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Summary: 
The focus of this study was the pathways for β-alanine production in Mycobacterium 
tuberculosis (Mtb), the causative agent of tuberculosis.  The major pathway for β-alanine 
production is the decarboxylation of L-aspartate by L-aspartate-α-decarboxylase (PanD).  
This enzyme is not essential for the survival for Mtb which implies that an alternative 
pathway for β-alanine production must exist.  We postulated that such a secondary 
pathway may be based on the oxidation of various polyamines by a polyamine oxidase to 
give the β-alanine precursor 3-aminopropanal, and therefore set out to find data in 
support of this hypothesis. 
Based on sequence homology to the FAD-dependent Saccharomyces cerevisiae polyamine 
oxidase Fms1, Mtb AofH was identified as a likely candidate.  The soluble expression and 
purification of AofH proved troublesome and lead to the investigation of various 
techniques to increase protein yield.  These methods include fusion to various tags, co-
expression with the protein chaperones, addition of scarce codon tRNA’s to the 
translation mixture and protein refolding.  AofH was eventually purified as fusions to the 
Nus and MBP proteins and its activity determined by analysis of the enzymatic reactions 
by TLC, reverse phase HPLC, ESI-MS and LC-MS.  TLC analysis indicated that 3-
aminopropanol formed as a product during polyamine oxidation, but this could not be 
confirmed by any of the more sensitive analytical techniques.  We set out to confirm the 
presence of the FAD cofactor in the enzyme by various methods and concluded that the 
AofH fusions did not contain FAD.  Efforts to refold the protein in the presence of FAD 
also failed.  From this study it is clear that the biochemical confirmation of the presumed 
activity of AofH will remain elusive until the enzyme can be purified in its active form, 
i.e. with FAD bound.  A genetic test for activity based on functional complementation 
studies of Escherichia coli ∆panD strains proved inconclusive since no difference in growth 
rate was found between cell transformed with the aofH gene and the negative control. 
We continued our studies of β-alanine biosynthesis by attempting the design of 
mechanism-based inhibitors for the PanD enzyme.  Various structural analogues were 
identified and tested by qualitative and quantitative methods.  Our results show that β-
substituted aspartate analogues may be good potential inhibitors of Mtb’s PanD protein 
and can thus be used in rational drug design. 
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Opsomming: 
In hierdie studie het ons gefokus op die biologiese padweë vir die vervaardiging van β-
alanien in Mycobacterium tuberculosis (Mtb), die organisme wat tuberkulose veroorsaak.  
Die hoofpadweg behels die dekarboksilering van L-aspartaat deur L-aspartaat 
dekarboksilase (PanD).  Siende dat hierdie ensiem nie noodsaaklik is vir die oorlewing 
van die organisme nie, is die gevolgtrekking gemaak dat daar ‘n alternatiewe padweg vir 
die produksie van β-alanien moet bestaan.  Ons hipotese was dat hierdie alternatiewe 
padweg die oksidasie van verskeie poliamiene deur ’n poliamien oksidase ensiem is om 
die β-alanien voorloper 3-aminopropanaal to vorm.  Die eerste deel van hierdie studie 
fokus op die bevinding van resultate ter ondersteuning van hierdie hipotese. 
 Gebaseer op DNA volgorde vergelykings met die poliamien oksidase Fms1 van die gis 
Saccharomyces cerevisiae, is die Mtb ensiem AofH as ’n moontlike kandidaat geïdentifiseer.  
Probleme is ondervind met die oplosbare uitdrukking en suiwering van hierdie ensiem.  
Om die oplosbaarheidsprobleem te oorbrug, is verskeie proteïen merkers aan AofH 
geheg.  Metodes om die opbrengs te vermeeder is ook ondersoek, insluitende die 
toevoeging tRNA’s van skaars kodons en die proteïene wat tydens die vouproses help 
fasiliteer. AofH is na vele probeerslae gesuiwer as ’n fusieproteïen saam met die proteïene 
Nus en MBP, waarna die aktiwiteit daarvan geanaliseer is deur gebruik te maak van 
dunlaag chromatografie, omgekeerde fase HPLC, ESI-MS en LC-MS.  Volgens die 
dunlaag chromatografie analise vorm 3-aminopropanol as ’n produk gedurende die 
oksidasie van die poliamiene.  Hierdie waarnemening kon egter nie bevestig word met 
enige van die meer sensitiewe analitiese tegnieke nie.  Toetse om die teenwoordigheid 
van FAD te bevestig, het gewys dat die kofaktor nie gebind het aan die ensiem nie.   Aan 
hand hiervan kan die onaktiwiteit van AofH verklaar word. 
Ons studie van β-alanien biosintese is voortgesit deur te konsentreer op die ontwerp van 
’n meganisties-gebaseerde inhibitor van die PanD ensiem.  Vir hierdie doeleindes is 
verskeie strukturele analoë van L-aspartaat geidentifiseer en getoets deur middel van 
kwalitatiewe en kwantitatiewe tegnieke.  Ons resultate wys dat β-gesubstitueerde 
aspartaatanaloë heel moontlik goeie inhibitors van die Mtb PanD ensiem mag wees en 
dus gebruik kan word in die rasionale ontwerp van medisynes. 
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C h a p t e r  1  
Introduction: 
The importance of β-alanine in pantothenate biosynthesis 
1.1  Introduction 
Tuberculosis (TB) is a disease that primarily affects the respiratory system and is 
estimated to be the second greatest cause of adult mortality among the infectious diseases.  
According to the World Health Organization TB is responsible for approximately two 
million deaths annually and the organization estimates that it infects a third of the world’s 
population.  A mere 50 years ago there was no cure for TB and today Mycobacterium 
tuberculosis (Mtb) strains have emerged that are resistant to all major anti-TB drugs.  Drug 
resistance arises mainly in the third world countries due to incorrect or partial treatments 
given.  The immune deficiency state caused by HIV also increases vulnerability to Mtb 
infections.  It has been estimated that 13% of AIDS deaths worldwide are due to TB.  
Currently treatments for TB include the vaccine Bacille Calmette-Guérin (BCG) and short 
course chemotherapy, but with the spread of multi-drug resistant Mtb and the HIV co-
infections the urgency to identify and develop new drugs still exist (1). 
1.2  Background 
TB is caused by the Gram-positive bacteria Mycobacterium tuberculosis.  Since its isolation 
in 1905 the Mtb strain H37Rv has found extensive application in biomedical research 
mainly because it has retained its full virulence.  The complete genome sequence of this 
strain has been determined, analyzed and published in 1998 by Cole et al. (2) Its genome 
contains ±4 000 genes and has a high guanine and cytosine content.  This is reflected in a 
bias towards certain amino acids (2).   
The problem with Mtb is that it has a natural resistance to many antibiotics that makes it 
difficult to treat.  A large part of this natural resistance can be contributed to the highly 
hydrophobic cell envelope that acts as a permeability barrier.  Mtb has an additional layer 
besides the normal peptidoglycan cell wall that is rich in unusual lipids, glycolipids and 
polysaccharides.  Another factor that contributes to the natural resistance is that the 
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genome encodes for many potential resistance determinants.  These include the hydrolytic 
or drug-modifying enzymes such as the β-lactamases and aminoglycoside acetyl 
transferases.  Mtb also have many potential drug-efflux systems such as the ABC-
transporters (2). 
In addition to Mtb’s inherent resistance, the pathogen also has the ability to persist within 
its host for extended periods of time without ever making the host ill.  This is what is 
known as latent or chronic infections.  It is estimated that only 10% of people with an 
intact immune system infected with Mtb will show any symptoms of the disease in their 
lifetimes.  For the pathogen to persist in its latent state, however, certain genes still need 
to be expressed and certain metabolic paths need to be maintained.  The genes necessary 
for the latent state survival fall into one of three categories.  Their gene products are either 
part of the respiratory enzymes or of the stress-related and metabolic enzymes or they are 
proteins involved in fatty acid biosynthesis (3). 
1.3  Pantothenate mediated virulence of Mtb 
As briefly mentioned above, the biosynthesis and metabolism of fatty acids play an 
important role in the replication and persistence of Mtb in the latent state.  It has also been 
found that the biosynthesis of pantothenate is essential for the growth of Mtb (4).  
Pantothenate or Vitamin B5 is the precursor in the biosynthesis of coenzyme A (CoA) and 
the acyl carrier proteins.  These metabolites have important functions in metabolic 
pathways like fatty acid metabolism, the tricarboxylic acid cycle and the biosynthesis of 
polyketides.  Pantothenate is supplemented to the diet of higher animals, but bacteria, 
plants and fungi can biosynthesize it de novo.  Since the biosynthesis pathway of 
pantothenate is absent in humans, this pathway is a possible drug target in Mtb.   
A study done by Jacobs et al. to design new TB vaccines focused on this biosynthetic 
pathway (5).  In this study they created a double deletion mutant of Mtb by deleting the 
panC and panD genes, the two genes involved in the de novo synthesis of pantothenic acid 
from L-aspartate.  The ∆panCD mutant was found to be auxotrophic for pantothenate.  
Full virulence was restored with the integration of the panCD wild type genes back into 
the ∆panCD mutant.  The viability of this deletion mutant as vaccine was tested by 
infecting severely compromised immune deficient (SCID) mice with the strain.  The 
survival rate of these mice where compared to that of control experiments where the mice 
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were infected with either the virulent H37Rv Mtb strain or with BCG vaccine.  Mice 
infected with the ∆panCD mutant survived noticeable longer (250 days) than those 
infected with the BCG vaccine (77 days) and the virulent strain (35 days).  It would thus 
appear that Mtb is dependent on pantothenate for its virulence.  
1.4  Pantothenate biosynthesis - An overview 
1.4.1  Biosynthetic pathway 
(R)-Pantothenate (1.1) (pantothenic acid, Vitamin B5) is the condensation product of β-
alanine (1.2) and (R)-pantoic acid (1.3).  This reaction is catalyzed by pantothenate 
synthetase (PanC) and is adenine triphosphate (ATP) dependent.  (Refer to Figure 1.1)   
Figure 1.1:  The biosynthetic pathway for the production of (R)-pantothenate (1.1) 
from its precursors β-alanine (1.2) and (R)-pantoic acid (1.3).  β-alanine is obtained by 
the decarboxylation of L-aspartate (1.6) and (R)-pantoic acid via a two step process in 
which the precursor α-ketoisovalerate (1.4) is hydroxymethylated to α-ketopantoate 
(1.5) and subsequently reduced. 
(R)-Pantoic acid is formed in two catalytic steps from its precursor, α-ketoisovalerate (1.4).  
This compound is also an intermediate in valine and leucine biosynthesis.  The first step is 
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catalyzed by ketopantoate hydroxymethyltransferase (PanB) and involves the 
hydroxymethylation of 1.4 to form α-ketopantoate (1.5).  The product is reduced to 
pantoic acid by ketopantoate reductase (PanE) in the presence of nicotinamide adenine 
dinucleotide phosphate (NADPH).  The second precursor of pantothenate, β-alanine (1.2), 
is formed by the decarboxylation of L-aspartate (1.6) by the enzyme L-aspartate-α-
decarboxylase (PanD) (6).  
1.4.2  The enzymes involved 
1.4.2.1  Ketopantoate hydroxymethyltransferase (PanB) 
Although the condensation of α-ketoisovalerate (1.4) with formaldehyde to form α-
ketopantoate (1.5) was already demonstrated chemically in 1942, the enzyme with the 
corresponding activity was only identified in 1957 (7). 
PanB has been overexpressed and purified from E. coli as a hexameric protein consisting 
of 28kDa subunits (6). Its analogue in Mtb (designated Rv2225) has also been cloned, 
overexpressed and purified to near homogeneity as the native protein and as a  
6х histidine (His-tag) fusion (7, 8).  The crystal structure of the Mtb PanD was solved to 
2.8Ǻ using gadolinium soaked crystals.  The subunit complexes Mg2+ to form a decameric 
structure with pentameric rings.  These rings are held together by C-terminal α-helices 
that switch around between promoters in opposite pentamers.  This helix swapping was 
not observed in the structures solved for the PanD-crystals of E. coli or N. meningitides (7). 
As far as the catalytic mechanism of PanB is concerned, the exact route is still unclear.  It 
is known that PanB is dependent on N5,N10-methylene tetrahydrofolate (met-THF) and 
that a divalent metal ion is required for substrate enolization.  All the proposed 
mechanisms (refer to Figure 1.2) start of with the coordination of 1.4 to Mg2+.  The 
coordination to the divalent metal ion is presumed to lower the pKa of the β-proton of 1.4 
which favors the abstraction thereof for enolate formation.  Sugatino et al. suggested that 
nucleophilic attack occurs via the enolate on the methylene group of the met-THF and 
that results in the breaking of the bond between N5 and the cofactor (Figure 1.2, route a).  
The hydrolysis of the newly formed C-N bond leads to the formation of 1.5 (8).  The 
second proposed mechanism starts of with ring opening of met-THF followed by 
deprotonation of Glu181, nucleophilic attack by 1.4 and hydrolysis (Figure 1.2, route b).  
The third mechanism (Figure 1.2, route c) involves the formation of formaldehyde by the 
hydrolysis of met-THF (7).  Of all the mechanisms, this one is the most unlikely since it is 
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known that the reaction proceeds via the inversion of stereochemistry at C-3 of 1.4 (6).  A 
free formaldehyde group would allow attack from both sides of the stereomeric centre 
and a racemate would form.    
 
Figure 1.2:  The 3 catalytic mechanisms proposed for PanB.  Routes a, b and c indicate 
the three postulated mechanisms for nucleophilic attack on met-THF.  Routes d and e 
are the two mechanisms for hydrolysis.  
As for the hydrolysis two possible routes are postulated.  The first method involves 
intramolecular attack of to the carboxylate ion to form ketopantolactone followed by 
hydrolysis (Figure 1.2, route d).  The second method involves nucleophilic attack by one 
of the H2O molecule that was coordinated to Mg2+ (Figure 1.2, route e).   
1.4.2.2  Ketopantoate reductase (PanE) 
There are more than 80 known sequences for putative ketopantoate reductases.  These 
homologues share very little sequence conservation with only nine concerved residues.   
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Three of these residues are glycines (Gly7, Gly9 and Gly12) that form part of the GXGXXG 
nucleotide binding motif.  This motif binds flavin and structurally forms part of the 
Rossmann-fold (7).  
PanE (also known as ApbA) has been cloned, overexpressed and characterized as a 
monomer of 34kDa in E. coli (6).  The Stenotrophomonas maltophilia PanE on the other hand 
is a multimeric protein consisting of a 30.5kDa subunits and multimeres of 87, 115, 140 
and 160kDa.  The size of the multimeres depends on the purification method used (7).  
Mtb PanE (Rv2573) is labeled as a gene that causes slow growth of the pathogen when 
mutated (9).  A search for this gene on the Tuberculist database (10) identified it as a 
conserved hypothetical protein with no known function.  No other information was 
obtained thus far. 
Two different reaction mechanisms have been proposed for this reduction.  The only 
differences between them are the residues that donate the proton to the keto acid and the 
residues that stabilize the γ-hydroxyl group by H-bonding.  In both mechanisms the si-
face hydrogen of NADPH attacks the carbonyl group of α-ketopantoate (1.5) (refer to 
Figure 1.3).  The resulting alkoxide is protonated by either Lys175 (1st mechanism) or Glu256 
(2nd mechanism) to form 1.3 (7). 
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Figure 1.3:  The basis mechanism of ketopantoate reductase (PanE) where α-
ketopantoate (1.5) is reduced to pantoic acid (1.3) in the presence on NADH. 
1.4.2.3  L-Aspartate-α-decarboxylase (PanD) 
Shive and Mascow (7) discovered the role of L-aspartate in pantothenate biosynthesis in 
1946.  They found that bacterial cellular growth was inhibited by β-hydroxyaspartate, but 
was stimulated when asparagine, pantothenate and aspartate were added to the growth 
media.  They took the experiment one step further and also found inhibition of cellular 
growth when a structural analogue of L-aspartate, cysteic acid, was added.  This growth 
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rate was restored when additional supplements of β-alanine and pantothenate were 
added to the growth media.  They concluded that β-alanine must be formed from  
L-aspartate.  
PanD forms part of a small class of pyruvoyl-dependent decarboxylases.  These enzymes 
undergo post-translation modification to form the catalytically active pyruvoyl group.  
Other enzymes in this class include the histidine decarboxylases, arginine decarboxylases, 
S-adenosylmethionine (SAM) decarboxylases and the phosphatidylserine decarboxylases 
(7).  The tetrameric Mtb PanD is translated into an inactive pro-enzyme, called the π-
protein (15,95kDa).  Activation of the enzyme occurs with the cleavage of the bond 
between Gly24 and Ser25.  The two subunits that form are labeled as the α-subunit 
(13.22kDa) that contains the pyruvoyl group at its N-terminal and the β-subunit (2.74kDa) 
with a carboxyl group at its C-terminal.  The covalently bound pyruvoyl group of PanD-α 
is the essential factor for catalysis (11).  
In the catalytic reaction (refer to Figure 1.4) the pyruvoyl group binds L-aspartate (1.6) to 
form a protonated imine (also known as a Schiff-base).  This binding interaction activates 
the L-aspartate for decarboxylation.  The hydrolysis of the Schiff-base leads to the release 
of β-alanine (1.2) and the enzyme (6).    
 
Figure 1.4:  Catalytic mechanism of aspartate-1- decarboxylase (PanD).  β-alanine (1.2) is 
formed by the decarboxylation of L-aspartate (1.6). 
The PanD’s from E. coli, Mtb and Helicobacter pylori were purified to near homogeneity as 
His-tag fusions.  The tetrameric enzyme consists of 10.8kDa subunits in E. coli (6) and 
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15.95kDa subunits in Mtb (11).  The crystal structures of these homologues were also 
solved and will be discussed in Chapter 4. 
1.4.2.4  Pantothenate synthetase (PanC) 
PanC was identified as early as 1952 in cell extracts of E. coli.  Since then the E. coli enzyme 
has been purified to near homogeneity and identified as an 18kDa homotetramer (6).  The 
Mtb homologue, a larger enzyme of 33kDa, has also been overexpressed and purified as a 
His-tag fusion (4).   
Unlike PanE the primary structure of PanC is relatively highly conserved with over 30 
amino acids that are identical in most of the homologues.  The crystal structures of the  
E. coli, Mtb and Thermus thermophilus homologues have been solved (7, 12).  According to 
the three dimensional structures of the Mtb and E. coli proteins, PanC belongs to the 
cytidylyl transferase family of proteins (13, 14).  The protein has a well defined N-terminal 
Rossmann fold that contains the active cavity and a C-terminal domain that acts as a 
hinged lid for this cavity.  Extensive work has been done to characterize the active site of 
the Mtb protein (7, 13, 14). 
PanC is an ATP dependent ligase.  The formation of the amide bond between pantoate 
(1.3) and β-alanine (1.2) is a two step process (Figure 1.5).   
N
NN
N
NH2
O
OHHO
O
P
O
P
O
P
-O
O O O
O-O-O-
C
O
O-
N
NN
N
NH2
O
OHHO
O
P
O
O
O-
C
O
HO
HO
PPi
NH2HOOC
1.21.3
H OH
N
H
COO-
O
1.1
HO
ADP
 
Figure 1.5:  The catalytic mechanism of pantothenate synthetase (PanC).  An amide 
bond forms between pantoate (1.3) and β-alanine (1.2) in the presence of ATP to from 
pantothenic acid (1.1). 
In the first step 1.3 and ATP forms pantoyl adenylate with the release of pyrophosphate.  
The second step is a nucleophilic attack by 1.2 on the intermediate to form pantothenate 
and AMP (15).  The presence of the pantoyl adenylate intermediate has been confirmed by 
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31P-NMR and with positional isotope exchange reaction within 18O-labeled ATP in the 
presence of D-pantoate (15).  
The reaction proceeds via a Bi Uni Uni Bi Ping Pong mechanism (Scheme 1.1).  This 
involves the initial binding of ATP followed by the binding of pantoate.  In the 
proceeding step pyrophosphate is released, followed by the binding of β-alanine and the 
release of pantothenate.  AMP is the last to be released.  This reaction is dependent on 
Mg2+ and has a pH optimum of 10.  Although Mg2+ is thought to be essential for the 
synthetase reaction, Mn2+ was also able to stimulate activity in Mtb (7). 
Enzyme Enzyme.ATP Enzyme.ATP.Pantoate Enzyme.Pantoate.AMP.PPi
Enzyme.Pantoae.AMP
Enzyme.Pantoate.AMP.β−alanineEnzyme.Pantothenate.AMPEnzyme.AMP
ATP Pantoate
PPi
Pantothenate
AMP
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Scheme 1.1:  Schematic representation of the Bi Uni Uni Bi Ping Pong mechanism as 
used in the pantothenate synthetase reaction (7). 
1.5  Essentiality of the pantothenate biosynthesis genes 
The same study that observed that Mtb displays pantothenate dependant virulence found 
that the ∆panCD mutant could persist in the host organism for over 8 months (5).  The 
organism has to obtain pantothenate from somewhere to survive, since it has been shown 
that fatty acid metabolism is one of the essential processes for survival in the latent state.  
Jacobs et al. postulated that an unidentified permease could be present to transport 
adequate amounts of pantothenic acid into the cells for survival, but not to restore 
virulence.  They go further to state that such pantothenate permeases have been described 
in Plasmodium falciparum and E. coli.  One problem though is that the intracellular life style 
of Mtb makes it difficult for it to obtain any essential nutrients from its host (5).   
In an important study Rubin et al. aimed to identify the genes essential for survival in 
Mtb.  This study included already characterized pathways as well as genes with unknown 
functions.  To determine essentiality, genes were systematically knocked out by 
transposon site mutagenesis, a method using Himar1-based transposon deliverance by a 
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transducing bacteriophage and transposon site hybridization (TraSH).  Interestingly, 
Rubin found that panC is essential for the survival of Mtb, but panD is not (9). 
Since pantothenate biosynthesis is essential in Mtb, the organism must be able to obtain  
β-alanine from an alternative source or via another route.  One of the sources postulated is 
a pantothenate salvage pathway that uses a permease, but until date no enzyme with this 
function has been identified in Mtb (5).  The second solution is that an alternative 
metabolic pathway must exist and this is what we set out to identify in this study.  
1.6  Alternative sources of β-alanine 
Apart from the PanD-catalyzed decarboxylation of L-aspartate there are four other 
pathways postulated to produce β-alanine.  These pathways include the catabolism of 
uracil, the degradation of polyamines, propionate degradation and cyanide metabolism in 
some plants.  Even with 5 different pathways to choose from, only the decarboxylation of 
L-aspartate and polyamine degradation are thought to be involved in the synthesis of  
β-alanine for pantothenate production.  The catabolism of pyrimidine may well 
contribute, but then only in a few species while propionate degradation and cyanide 
metabolism occur only in organisms that either do not synthesize pantothenate or where 
the pathways are presumed not to contribute significantly to the cellular pool of β-alanine 
(7).  The four alternative routes are reviewed briefly. 
1.6.1  Degradation of uracil 
This pathway is present in the yeast Saccharomyces kluyeri, in mammals who use it for the 
biosynthesis of anserine and carnosine (mammals do not biosynthesize pantothenate de 
novo) and in other eukaryotes like Drosophila melanogaster in which β-alanine is a 
component of the cuticle (7).   
The degradation of uracil (1.7) is initiated by its hydrogenation at the double bond to form 
5,6-dihydouracil (1.8) by dihydrouracil dehydrogenase, followed by hydrolytic ring 
opening to form β-ureidopropionate (1.9).  β-alanine (1.2) is formed by the deamination 
and decarboxylation of 1.9 (Figure 1.6).  The reduction reaction is catalyzed by 
dihydrouracil dehydrogenase in the presence of either reduced nicotinamide adenine 
dinucleotide (NADH2) or reduced nicotinamide adenine dinucleotide phosphate 
(NADPH2) (16, 17).   
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Figure 1.6: The degradation of uracil (1.7) to β-ureidopropionate (1.9) to β-alanine 
(1.2). 
The degradation of uracil to β-alanine does not occur in baker’s yeast, S. cerevisiae (18), 
and this pathway is also reported to be absent in bacteria (7).  There is some controversy 
on this point, since it has been reported that there are certain E. coli-mutants that do 
indeed get their β-alanine from this pathway (19).  The reports by Slotnick et al. however 
discount uracil as the β-alanine source, but clearly states the use of dihydrouracil as 
growth factor (20, 21).  It has been shown that β-ureidopropionate and 5,6-dihydrouracil 
provide sufficient nutrition to maintain static stocks in auxotrophic E. coli strains but this 
pathway cannot support growth unless an excess of these metabolites is fed into the 
system (7).  Studies done by Cronan et al. also discarded dihydrouracil as a growth factor.  
They concluded that the decarboxylation of L-aspartate is definitely the major route for 
β-alanine production (22).  This is confirmed by the fact that bacteria normally first 
oxidizes uracil to barbiturate.  The hydrolytic ring opening of barbiturate leads to the 
formation of malonate and urea and not β-alanine (16).  In conclusion, if this pathway is 
present in Mtb, it will probably not provide sufficient amounts of β-alanine in the absence 
of the decarboxylation of L-aspartate to account for the steady state survival of the 
organism (7).  
1.6.2  Degradation of polyamines 
Polyamines are polybasic hydrocarbons of which the most well known are spermine, 
spermidine, putrescine and cadaverine.  These compounds interact with the acidic cell 
components DNA, RNA, nucleotides and proteins.  Many reactions with the polyamines 
have been characterized in vivo, which include the synthesis of DNA, RNA, proteins, 
stabilization of tRNA and increasing translation efficiency and fidelity under conditions 
of reduced Mg2+ concentrations (23, 24).  Polyamines also have applications in 
fundamentally important processes including wound healing, tissue growth and tissue 
differentiation.   
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Degradation of the polyamines occurs in the presence of the amine oxidases to form a 
variety of smaller amine containing compounds (19).  To form β-alanine a polyamine is 
first oxidized to 3-aminopropanal (1.10) in the presence of O2 (Figure 1.7).  This is 
followed by further oxidation to form the carboxylic acid, β-alanine (1.2).  This reaction is 
catalyzed by the aldehyde dehydrogenases (25).  The oxidation reaction is flavin-
dependent and the gene sequence of the oxidation enzyme has sequence homology to the 
enzymes in the flavin dependent amine oxidizes enzyme family. 
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Figure 1.7:  The oxidation of a polyamine to β-alanine. 
This pathway is already well documented in the baker’s yeast, S. cerevisiae.  This is also 
the pathway we identified and attempted to characterize in Mtb. 
1.6.3   Propionate degradation 
As already mentioned this pathway is not regarded as a source of β-alanine for 
pantothenate biosynthesis.  Propionyl-CoA (1.11) is dehydrogenated to acryloyl-CoA 
(1.12) that in turn is hydrolyzed to form β-hydroxypropionyl-CoA (1.13) (refer to Figure 
1.8).  This product is hydrolyzed to β-hydroxypropionate (1.14).  The oxidation of 1.14 and 
the transamination of the resulting malonate semialdehyde (1.15) leads to the formation of 
β-alanine (1.2) (7). 
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Figure 1.8: Biosynthesis of β-alanine via propionate degradation 
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1.6.4  Cyanide metabolism 
This three step degradation reaction has not been characterized in any organism to date 
and is also presumed not to be the primary source of β-alanine in any organism.  As can 
be seen in Figure 1.9, the reaction is initiated by the interaction of cysteine (1.15) with a 
free cyanide ion to form β-cyanoalanine (1.16).  This product is hydrolyzed to asparagine 
or decarboxylated to form 3-aminopropionitrile (1.17).  Hydrolysis of 1.17 forms β-alanine 
(7). 
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Figure 1.9:  Hypothetical biosynthesis of β-alanine via cyanide metabolism 
1.7  Degradation of polyamines in S. cerevisiae 
The degradation of polyamines in the yeast S. cerevisiae occurs in two steps.  In the first 
step the polyamine is oxidized by the polyamine oxidase Fms1 which was identified by 
White et al. (19) and purified to near homogeneity and characterized by Landry et al. (24).  
The aldehyde dehydrogenases required for the oxidation of the aldehyde to β-alanine is 
Ald2 and/or Ald3 (26).  A brief overview of these enzymes follows. 
1.7.1  Polyamine oxidase:  Fms1 
1.7.1.1  Background 
It was originally reported that S. cerevisiae needed exogenous pantothenic acid for growth.  
Later it was found that it only needs a β-alanine supplement.  This implied that  
S. cerevisiae has all the enzymes necessary for de novo biosynthesis of pantothenate except 
for a PanD homolog.  Consistent with this homologs have been identified for all the 
enzymes in the pantothenic acid biosynthetic pathway except for PanD.  The gene ECM31, 
thought to be involved in cell wall maintenance, has homology to panB.  YIL145c is a panC 
orthologue that has been shown to be functional in E. coli and the putative YHR063c has 
structural homology to panE.  To find a source for β-alanine White et al. studied the 
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putative polyamine oxidase Fms1.  Functional screens done with Fms1 indicated that this 
enzyme was rate limiting in β-alanine and pantothenic acid biosynthesis and that 
overexpression of the gene lead to β-alanine excretion into the growth media.  The role of 
Fms1 in β-alanine production from the polyamines was confirmed when it was found that 
all the enzymes in the polyamine biosynthesis pathway are necessary for β-alanine 
production (19). 
1.7.1.2  Characteristics 
Fms1 is a protein of 508 amino acids with sequence homology to polyamine oxidase of 
Candida albicans, human monoamine oxidase A and B and the peroxisomal 
acetylspermidine oxidase Aso1p of Candida boidinii (24).  It contains the GXGXXG 
dinucleotide FAD recognition motif and it has been experimentally determined that it 
binds FAD non-covalently in a molar ratio of 1:1.  Substrates for the enzyme include 
spermine (Spm), N1-acetylspermine (N1-spm), N1-acetylspermidine and to a lesser extend 
N8-acetylspermidine (N8-spd).  Of these only the oxidation of spermine yields β-alanine as 
a final product (24). 
1.7.2  Aldehyde dehydrogenases:  Ald2 and Ald3 (26) 
1.7.2.1  Background 
The complete yeast genome encodes for 7 different members of the aldehyde 
dehydrogenase family and any one of them could hypothetically be involved in β-alanine 
production.  Two of these, ALD2 and ALD3, encode closely related cytosolic enzymes that 
are induced in response to stress or on ethanol media.  ALD4 encodes the major  
K+-dependent mitochondrial enzyme and ALD5 encodes the minor one.  ALD5 is also 
induced on ethanol.  The Mg2+ mitochondrial enzyme is encoded by ALD6.  Of the two 
remaining sequences MSC7/YHR039c encodes a protein with sequence homology to an 
aldehyde dehydrogenase that affects meiotic sister-chromatid recombination and 
YMR110c is a hypothetical protein.  Even though multiple gene sequences exist, only 
acetaldehyde has been identified as a physiological substrate and only Ald4p and Ald6p 
are involved in oxidizing this substrate to acetate.  Ald2p, Ald3p and Ald5p are not 
involved in this process.  Ald5p also has been postulated to have an undefined role in 
heme biosynthesis.  Furthermore, Ald4p and Ald5p are mitochondrial enzymes as 
opposed to Ald2p, Ald3p and Ald6p which are cytosolic enzymes.  This may make Ald4p 
and Ald5p unavailable for the oxidation of 3-aminopropanal since is most likely produced 
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and consumed in the cytosol.  Studies with deletion mutants done by White et al. revealed 
that only the double deletion mutant ∆ald2∆ald3 showed complete pantothenate 
auxotrophy.  This auxotrophy was lifted by introducing a plasmid that contains either of 
the two gene sequences.  They also showed that although there is a significant degree of 
amino acid conservation between the aldehyde dehydrogenases, only ALD2 and ALD3 
could be implicated in β-alanine biosynthesis. 
1.7.2.2  Characteristics 
It was shown that ALD2 and ALD3 functions downstream from FMS1 and oxidizes 3-
aminopropanal to β-alanine.  Although there is 91% amino acid conservation between 
Ald2p and Ald3p, a degree of functional specialization does exist.  A mutant strain 
without the ALD2 gene is partially defective for pantothenate biosynthesis.  This leads to 
the conclusion that Ald2p is responsible for the majority of β-alanine production.  By 
placing the ALD2-mutant under K+- or Na+-induced osmotic stress, the defect seizes.  
Since it is known that transcription of Ald3p is osmo-induced (27) a sufficient rate of 
conversion from 3-aminoproponal to β-alanine in vivo should occur with this enzyme.   
1.8  Identification of AofH 
To identify a possible polyamine oxidase in Mycobacterium tuberculosis, a sequence 
homology search was done of FMS1 against the Mtb genome.  The orthologue that 
aligned the best was designated aofH (amine oxidase flavin dependent protein) or Rv3170 
(10).  According to the Tuberculist database AofH is a putative monoamine oxidase 
(MAO) that is flavin dependent.  An amino acid alignment of aofH and FMS1 in ClustalW 
shows that aofH is 60 amino acids shorter than FMS1.  Of these amino acids 99 residues 
match exactly, 88 residues are closely related, a further 60 residues align to a degree and 
201 residues show no similarity at all.  The enzyme Fms1 was identified as a member of 
the Glutathione reductase (GR) structural subfamily of the FAD-containing protein 
family.  One of the most conserved sequences of this family is the N-terminally located 
motif xhxhGxGxxGxxxhxxh(x)8hxhE where x = any residue and h = any hydrophobic 
residue (28).  This motif normally comprises part of the Rossmann fold.  This sequence is 
conserved in aofH along with the GxGxxG FAD binding domain (Figure 1.10).  This 
indicates that AofH may well be part of the GR enzymatic family and confirms the FAD 
dependence postulate. 
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Figure 1.10:  Sequence alignment of AofH and Fms1 constructed in T-COFFEE (29) 
and the sequence obtained from Tuberculist (10) and SGD™ (30).  
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1.9  Conclusion 
TB is still a very relevant problem in the African Health context today and the need for 
new drugs and the identification of new drug targets exist.  In the search for new drug 
targets we focused on the biosynthesis of pantothenate since it is an essential process in 
Mtb pertaining to the virulence of the pathogen.  Of the enzymes involved in this process 
PanD, the enzyme that catalyses the decarboxylation of L-aspartate to β-alanine, was 
found not to be essential.  If this is the case, Mtb must be able to obtain β-alanine by either 
a permease or another biosynthetic route.  Currently there are four alternative pathways 
known for the production of β-alanine of which the degradation of polyamines seems to 
be the most likely alternative to obtain this metabolite.  This pathway has been well 
characterized in the yeast S. cerevisiae that uses the polyamine oxidase Fms1 and the 
aldehyde dehydrogenases Ald2 and Ald3.  Based on this we set out to identify the 
alternative pathway for β-alanine production as the degradation of polyamines. 
1.10  Aims of this thesis 
The main aims of this project are to clone and express AofH solubly and to determine the 
activity of the enzyme.  With the activity known, the substrates of choice can be identifed 
and used in the rational design of mechanism based inhibitors for the enzyme. 
 The second aim is to study the inhibitory effects of small molecules on the enzyme that 
supplies the main source of β-alanine to Mtb, L-aspartate-α-decarboxylase (PanD).  To do 
this however methods have to be developed to screen these molecules both quantitative 
and qualititative.  Once this is done we want to design mechanism based inhibitors that 
are specific for PanD. 
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C h a p t e r  2  
Cloning, expression and purification of AofH: 
A closer look at different solubilization and purification strategies 
2.1  Introduction 
AofH was identified as a possible polyamine oxidase in Mycobacterium tuberculosis.  With 
the gene sequence known, the aofH-gene could be amplified from Mtb genomic DNA, 
ligated into an expression vector and overexpressed.  This chapter focuses on the cloning 
and soluble expression of AofH. 
2.1.1  Cloning and initial expression trials 
The aofH DNA sequence was amplified from genomic DNA of Mtb strain H37Rv with the 
introduction of an N-terminal NdeI-site and a C-terminal XhoI-site.  After restriction 
digestion with these enzymes, the PCR product was subcloned into pET28a(+).  This 
plasmid is part of the Novagen pET expression system and introduces an N-terminal 
6×histidine-tag (His-tag) to the protein.  The His-tag facilitates affinity purification of the 
protein by coordinating to Ni2+ (discussed later).  The formation of the construct was 
confirmed by screening and sequencing.  Expression trials were used to determine the 
conditions for the most efficient AofH overexpression.  These conditions included the 
temperature at which the expression was induced with isopropyl-β-D-thiogalactoside 
(IPTG), time of growth after induction and the concentration of IPTG used.  Except when 
the induction amount of IPTG was varied, all expression trials and large scale expressions 
were done from an E. coli B-strain, either BL21 (DE3) or BL21*(DE3).  For the variation of 
IPTG amounts Tuner (DE3) cell strain were used as it is a lac permease deletion mutant 
that allows uniform entry of IPTG into cells and thus provides strict concentration-
dependent control of induction.   
2.1.2  Attempts at solubility 
To obtain soluble expression of AofH, we initially focused on fusing different tags to the 
protein and evaluating the degree of expression obtained of the fused protein.  To do this 
new expression plasmids, which contained the new tag and the aofH gene sequence, had 
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to be created.  For this we moved towards the Invitrogen Gateway™ system.  This system 
allows the formation of expression clones by adding together an entry plasmid (pENTR), 
containing the gene sequence, and a destination plasmid (pDEST), containing the tag, 
with an enzyme mixture dubbed “LR clonase” to form the new expression plasmid 
(pEXP) that contains both the tag and target sequence.  (Refer to Figure 2.1). 
 
 
Figure 2.1:  The Gateway LR reaction (1).  The entry clone (pENTR) combines with the 
destination clone (pDEST) in the presence of LR clonase to from the expression clone 
(pEXP).  KnR = kanamycin resistance and ApR = ampicillin resistance.  (Reproduced 
from the GIBCO BRL Gateway™ cloning technology Instruction manual, version A) 
The entry plasmid used was pENTR4N.  This plasmid was derived from the commercial 
plasmid pENTR4 in which the NcoI-site has been mutated to an NdeI-site (2).  The 
amplified aofH DNA was ligated into pENTR4N using the XhoI and NdeI restriction sites.   
From there aofH was successfully subcloned into pDEST15 (GST-tag), pDEST566 (His-
MBP-tag), pDEST544 (His-Nus-tag), pET160-DEST (His-LumioTM-tag), pET160-GST-DEST 
(His-GST-LumioTM-tag), pBAD-DEST49 (thioredoxin-tag) and pYES-DEST52.  A summary 
of the plasmids and tags used in this study are given in Table 2.1. 
    
Table 2.1:  A summary of the plasmid used in this study, the application they were used for and the result obtained. 
Plasmid Fusion tag Parents Method of construction 
Source of 
parent  Application Expressed Soluble Purified Section 
pET28a(+) -
aofH 6×His 
pET28a(+) 
aofH PCR 
product 
Restriction 
digests   and 
ligation 
Novagen Expression trials √ X X 2.1.1 
pENTR4N-
aofH N/A 
pENTR4N 
aofH PCR 
product 
Restriction 
digests and 
ligation 
Created by 
Leisl 
Brand  
Entry vector for 
LR reactions N/A N/A N/A 2.1.2 
pEXP15-aofH GST pDEST15 pENTR4N-aofH LR reaction Invitrogen 
Expression trials/ 
Purification √ √ X 2.2.1 
pEXP566-
aofH 6×His-MBP 
pDEST566 
pENTR4N-aofH LR reaction 
Cynthia 
Kinsland 
Expression trials/ 
Purification √ √ √ 2.2.3 
pEXP544-
aofH 6×His-Nus 
pDEST544 
pENTR4N-aofH LR reaction 
Cynthia 
Kinsland 
Expression trials/ 
Purification √ √ √ 2.2.4 
pET160-EXP-
aofH 
6×His + 
LumioTM 
pET160-DEST 
pENTR4N-aofH LR reaction Invitrogen Purification √ X X 2.2.5 
pET160-EXP 
GST-aofH 
6×His-GST 
+ LumioTM 
pET160-GST- 
DEST 
pENTR4N-aofH 
LR reaction 
Created by 
Leisl 
Brand  
Purification √ √ X 2.2.2 
pBAD- 
EXP49-aofH 
His-Patch 
thioredoxin 
PBAD-DEST49 
pENTR4N-aofH LR reaction Invitrogen 
Purification/ 
Complementation √ X X 
2.2.6 
3.5.1 
pYES-
EXP52-aofH N/A 
pYES-DEST52 
pENTR4N-aofH LR reaction Invitrogen 
Expression trials 
Complementation X X X 
2.4.1 
3.5.2 
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2.1.3  Expression of AofH fusions 
The rate of cell growth and protein expression is important factors for the expression of 
foreign proteins from the E. coli system.  The solubility of the target protein fusions was 
tested initially by expression trials at 37˚C for a set period of time.  If soluble expression 
was not obtained, the following three parameters, all pertaining to rate of cell growth and 
protein expression, where changed.   
1. By transforming the plasmid into the Tuner (DE3) cell strain, the IPTG concentration 
with which are induced could be changed.  In the T7 promoter systems we use, T7 
RNA polymerase induces expression of the plasmids containing the target sequence.  
The IPTG-inducible lacUV5 promoter controls the expression of T7 RNA polymerase 
in the host strain.  By changing the amount of IPTG used for induction, the expression 
of T7 RNA polymerase can be controlled and subsequently the rate of protein 
expression (3).  In our experiments we induced with IPTG to final concentration of 
1mM, 0.75mM, 0.5mM, 0.2mM, 0.1mM and 0.05mM.  
2. Another parameter that controls the rate of expression is the temperature at which 
induction and expression occurs.  The decrease in temperature decreases the rate at 
which proteins are synthesized and may in some cases enhance solubility (4).  All 
expression trials were at 15˚C, 20˚C, 25˚C, 30˚C and 37˚C. 
3. The third parameter that was varied is the period of incubation after induction.  Too 
short expression times may lead in too little protein being expressed, while too long 
incubation times may lead to protease degradation of the proteins (5).  In addition the 
overgrowth of the culture may lead to overload of the bacterial synthetic apparatus 
and promote the formation of inclusion bodies (3).  All our experiments were 
incubated for 2 h, 4h or overnight. 
Expression was induced when an optical density at 600nm (OD600) of 0.6 was reached 
(mid-log phase).  The expression of the different AofH fusions is discussed in the next 
section. 
2.2  Attempts at native expression and purification 
Our original attempt to express AofH was as His-AofH from pET28a(+).  Soluble 
expression was not obtained and this led to the investigation of different fusion tags.   
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2.2.1  GST-tag 
The first tag we tried was the 26kDa glutathione-S-transferase tag (GST) that has its origin 
from Schistosoma japonicum. This tag is found in the commercial vector, pDEST15 (6).  
Soluble GST-AofH was obtained with induction with 0.5mM IPTG at 37˚C and leaving the 
expression for 3 hours (Figure 2.2). 
 
Figure 2.2:  Soluble expression of GST-AofH.  Lane 1- marker.  The following lanes are 
the soluble protein samples induced with the following final concentration of IPTG 
and grown for 3h:  lane 2 – 1mM, lane 3 – 0.75mM, lane 4 – 0.5mM, lane 5 – 0.2mM, 
lane 6 – 0.1mM, lane 7 – 0.05mM.  Lane 8 –sample induced with 0.5mM IPTG and 
grown overnight 
Purification of the GST-AofH fusion from the bacterial lysate was attempted with affinity 
chromatography on the ÄKTAprime-system.  This system is a compact, automated liquid 
chromatography system that simplifies the process of purification by affinity 
chromatography.  The GST-tag binds to the glutathione matrix of the 1ml GSTrap FF 
column.  Elution of the tagged protein is obtained by addition of reduced glutathione to 
the elution buffer. 
The first attempt to purify GST-AofH made use of His-tag binding buffer (20mM Tris-
HCl; 150mM NaCl; pH 7.3) and the elution buffer recommended by the suppliers (20mM 
Tris-HCl, 10mM reduced glutathione, pH 8.0).  Chromatograhy was recorded with a UV 
detector at 280nm to determine when the protein elutes.  Two different purification 
methods were used as discussed below and in both instances no purification was 
obtained. 12% SDS PAGE analysis of the purification showed that the protein never 
bound to the column. 
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In the effort to purify GST-AofH we experimented with different protocols for the 
purification runs, buffer compositions and even tried a new column.  The different runs, 
buffer changes and detection methods used are summarized in Table 2.2. 
Table 2.2:  Experimental changes for purification of GST tagged proteins 
Change 
Self 
program-
med run 
Tem-
plate  
run 
Manual 
controlled 
run 
Detect 
protein Reason for change 
Initial run √ √  UV detector 
at 280nm 
No protein purified 
Add DTT to 
buffers 
√   UV detector 
at 280nm 
Cleave disulfide bonds 
that may have formed in 
protein 
Change 
binding buffer 
to PBS + DTT 
√ √  UV detector 
at 280nm 
Exchange the Tris buffer 
for phosphate buffers. 
Slower 
injection step 
√ √  UV detector 
at 280nm 
Increase efficiency of 
protein binding to 
column 
Shorter wash 
steps 
√   UV detector 
at 280nm 
Reduce changes of losing 
protein 
Elution buffer 
+40mM 
reduced 
glutathione 
  √ Bradford 
reagent 
Higher elution efficiency 
due to increase affinity 
binding of glutathione 
Elution buffer 
+ 200mM 
NaCl 
  √ Bradford 
reagent 
Increase ionic to increase 
elution affinity 
Elution buffer 
+ 0.1% Triton 
X-100 
  √ Bradford 
reagent 
Non-ionic detergent to 
prevent hydrophobic 
interactions which may 
prevent solubility and 
elution of fusion proteins 
The self-programmed run mentioned in Table 2.2 consist of (excluding column 
equilibration and injection of the protein onto the column) a wash step of 10 column 
volumes (CV) of binding buffer followed by a wash step with 15 CV of 15% elution buffer 
(final concentration of 1.5mM reduced glutathione) to remove any non-specifically bound 
proteins.  The protein was eluted with 20 CV of 100% elution buffer.  A flow rate of  
1ml.min-1 is maintained throughout the run.  The template run is pre-programmed on the 
ÄKTAprime-system for purifications of GST fusions.  The only difference between the self-
programmed run and the template run is that the wash step with 15% elution buffer was 
omitted from the template run.  The manual run was controlled from the user interface 
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based on the observations made from the UV chromatogram being recorded during the 
run.   
The changes in buffer composition were made according to the trouble-shooting guide in 
the Amersham GST Instruction manual (6).  One of the methods suggested to increase 
binding efficiency of the protein to the column is to add dithiothreitol (DTT) to the lysate 
mixture before lysis.  DTT, a reagent that cleaves disulfide bonds, was added to both 
buffers to a final concentration of 10mM and the purification runs repeated, without 
success.  The binding buffer was changed to PBS-buffer (140mM NaCl, 2.7mM KCl, 10mM 
Na2HPO4, 1.8mM KH2PO4, 10mM DTT, pH 7.3), which is the buffer recommended by 
Amersham.  Milder sonication conditions were also used to eliminate the change of 
denaturation of the tagged protein during cell lysis.  The injection tempo while the protein 
sample was loaded on the column was also lowered from 1.0ml.min-1 to 0.5ml.min-1.  No 
protein was purified.  
Further attempts to elute the GST-protein from the column included limiting the time and 
volume of column washing, increasing the concentration of reduced glutathione from 10 
to 40mM in the elution buffer and increasing the ionic strength of the elution buffer by 
adding 200mM NaCl.  These purifications were performed manually by changing the 
parameters on the ÄKTAprime-system and adding Bradford reagent to an aliquot of the 
fractions that were assumed to contain protein.  A non-ionic detergent, Triton X-100, was 
also added to a final concentration of 0.1% to the elution buffer to counter any non-
specific hydrophobic interactions that may prevent solubilization and elution.  After 
careful experimentation with all the different elution buffers and obtaining no results a 
new column was tested.  This was also unsuccessful.  
2.2.2  His-GST 
Since the problems experienced with the GST-AofH fusion where all purification related, 
a fusion was created that adds a His-tag in front of the GST-tag.  This combination tag is 
found in pET160-GST-DEST, a plasmid that was created in our lab by Ms. Leisl Brand 
from the commercial plasmid pET160-DEST, which contains a His-Lumio™ tag.  pET160-
GST-DEST was created by inserting the GST tag between the His and Lumio™ tags.  This 
affords the real tag to be a fusion between the His, Lumio™ and GST tags, but since only 
the His-tag is important for purification and the GST-tag for solubility, it is designated 
His-GST.   
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As can be seen from the 12% SDS PAGE gel in Figure 2.3 soluble expression of the 76kDa 
protein was easily obtained at all IPTG concentrations.  Large-scale overexpression was 
induced with a final concentration of 0.1mM IPTG at 37˚C and the expression left 
overnight. 
 
Figure 2.3:  The 12% SDS-PAGE gel of the cell free lysate samples to determine the 
optimum amount of IPTG to obtain soluble His-GST-AofH.  All expressions were 
performed at 37˚C and cultures were grown overnight.  The samples are as follows:  
Lane 1- marker, Induced with final concentration IPTG:  lane 2 – 1mM, lane 3 – 
0.75mM, lane 4 – 0.5mM, lane 5 – 0.2mM, lane 6 – 0.1mM, lane 7 – 0.05mM  
Purification of the enzyme by affinity chromatography on a 1ml HiTrap Chelating column 
with the ÄKTAprime –system failed (data not shown).  As in the case of GST-AofH, the 
protein bands were clearly visible on the 12% SDS PAGE gels in the crude extract and 
flow through samples.  As in the previous cases the protein thus expresses solubly, but 
does not bind to the column.  The purifications were tried by replacing the HiTrap 
chelating columns with a Sigma Ni2+-NTA column.  These columns already have Ni2+ 
chelated to the resin.  The new column made no a difference.   
Since we know His-GST-AofH does express solubly and the problem lies with the binding 
interaction of the protein to the column, we tested different buffers with different pH 
values for the purification.  The buffer compositions are given in Table 2.3.  The enzymes 
were purified on small scale using the batch purification method and buffer combinations 
given in Table 2.4.  The fractions were analyzed on 12% SDS PAGE gels as shown in 
Figure 2.4.  
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Table 2.3:  The composition of the different buffers used for the purification of His-GST-AofH. 
 Identifier Composition pH Binding/ 
Elution 
Source 
His-tag 
binding 
buffer 
20mM Tris-HCl 
500mM NaCl  
5mM Imidazole 
pH 7.9 
 
Binding Our standard 
binding 
buffers 
His-tag 
elution buffer 
20mM Tris-HCl 
500mM NaCl 
50mM Imidazole 
pH 7.9 Elution Our standard 
elution buffer 
PBS 140mM NaCl 
2.7mM KCl 
10mM Na2HPO4 
1.8mM KH2PO4 
pH 7.3 
 
Binding (6) 
Buffer A 20mM Tris-HCl 
100mM NaCl 
10mM β-mercaptoethanol 
pH 6.7 
 
Binding Protein 
refolding 
(8) 
Buffer A 
elution 
20mM Tris-HCl 
100mM NaCl 
10mM β-mercaptoethanol 
600mM imidazole 
pH 8.0 Elution Protein 
refolding 
(8) 
High Tris 50mM Tris-HCl 
20mM KCl 
10mM MgCl2 
pH 7.6 Binding Had in 
laboratory 
Tris-EDTA 10mM Tris-HCl 
1mM EDTA 
0.8% MgCl2 
pH 
7.75 
 
Binding (9) 
HEPES 20mM HEPES 
300mM NaCl 
5mM β-mercaptoethanol 
pH 8.0 
 
Binding (7) 
His-select 
binding 
buffer 
50mM Na3PO4 
300mM NaCl 
10mM imidazole 
pH 8.0 Binding (10) 
His-select 
elution buffer 
50mM Na3PO4 
300mM NaCl 
250mM imidazole 
pH 8.0 
 
Elution 
 
(10) 
 
From these results it seemed that purification was obtained with Tris-buffer with added 
β-mercaptoethanol and the phosphate buffers.  The experiments were scaled up using 
PBS as binding buffer and the His-tag elution buffer (Tris-buffer, Table 2.3) for 
purification on the ÄKTAprime-system with the flow rate during injection decreased to 0.1 
ml.min-1.  The upscaling proved to be unsuccessful. 
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Table 2.4:  Experimental set-up for purifications of His-GST-AofH with different buffers. 
Experiment 
number 
Identifier Binding 
Buffer 
Elution 
Buffer 
1 High Tris High Tris His-tag  
elution buffer 
2 Tris + Imidazole His-tag  
binding buffer 
His-tag  
elution buffer 
3 Tris + EDTA Tris-EDTA His-tag  
elution buffer 
4 Tris + 
β-mercaptoethanol 
Buffer A Buffer A elution 
5 Phosphate PBS His-select  
elution buffer 
6 Phosphate + 
imidazole 
His-select  
binding buffer 
His-select  
elution buffer 
7 HEPES HEPES His-tag  
elution buffer 
 
 
Figure 2.4:  SDS PAGE gels of His-GST-AofH purifications with different buffer 
combinations.  The gel on the right is of the proteins that did not bind to the resin 
(unbound proteins, flow through) and the gel on the left of the purified proteins.  
Lanes 1 – marker.  The rest of the lanes indicate the buffer combinations used as given 
in Table 2.4:  Lanes 2 – 1, lanes 3 – 2, lanes 4 – 3, lanes 5 – 4, lanes 6 – 5, lanes 7 – 6 and 
lanes 8 – 7. 
Since purification was obtained with the batch method, but not on large scale, a manual 
purification was attempted using the same resin as was used for the batch purifications.  
The fractions obtained from the manual purification were analyzed on a 12% SDS PAGE 
gel (Figure 2.5) and a degree of purification was obtained between the flow through (the 
proteins that did not bind to the column) and the wash peak (non-specifically bound 
proteins).  Furthermore the protein did not express as well as in earlier experiments.  SDS 
PAGE analysis indicated a band at 50kDa, the size of AofH without the GST-tag (His-
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GST-AofH = 76kDa).   The question arose if this is AofH without a tag, but attempts to 
purify this band failed and its identity could thus not be confirmed.  
 
Figure 2.5:  Gel picture of the manual purifications of His-GST-AofH. 
Lane1 – marker, lane 2 – flow through (attempt 1), lane 3 – Purified protein  
(attempt 1), lane 4 – flow through (attempt 2), lane 5 – purified protein (attempt 2), 
lane 6 – crude extract from the bacterial lysate that contains a protein band the size of 
AofH.  This band could not be identified and is therefore indicated as unknown. 
Purification of His-GST-AofH from crude bacterial lysate was attempted with gradient 
elution in which the concentration of imidazole was increased very gradually.  For each 
new concentration the column was eluted with 2 CV of the elution buffer in steps with 
imidazole concentrations from 1.73 to 100mM.  SDS PAGE analysis indicated that the 
bands at 76kDa (GST-AofH) and 26kDa (GST) were absent, but the unknown band at 
50kDa again appeared. 
2.2.3  His-MBP-tag 
Maltose binding protein is a 43.277kDa fusion tag that is thought to be a far better fusion 
partner than GST to increase solubility (4).  This tag is fused C-terminally to a His-tag in 
the pDEST566 vector.   
One round of expression trials were performed in BL21* (DE3) at 37˚C.  According to the 
SDS PAGE analysis (Figure 2.6) the 93.3kDa fusion expresses solubly, although not very 
well, at all the IPTG induction concentrations.  The cell free (soluble proteins) and whole 
cell (total cell lysate) SDS PAGE analyses are shown. 
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Figure 2.6:  The 12% SDS PAGE gel analysis of the expression trials of His-MBP-AofH.  
The expressions were induced with different concentrations IPTG at 37˚C and 
expressed for 3 hours after induction.  The gel on the left is the cell free lysate samples 
that contains the soluble proteins and the gel on the right the whole cell samples.  
Lane 1- marker, Induced with final concentration IPTG:  lane 2 – 1mM, lane 3 – 
0.75mM, lane 4 – 0.5mM, lane 5 – 0.2mM, lane 6 – 0.1mM, lane 7 – 0.05mM 
Large-scale expressions were induced with a final concentration of 0.2mM IPTG at 37˚C 
and grown for 3 hours. The protein was easily purified using affinity chromatography on 
a 1ml HiTrap Chelating column with the ÄKTAprime –system (refer to Figure 2.7). 
 
Figure 2.7:  The 12% SDS PAGE gel analysis of the large scale expression of His-MBP-
AofH.  Lane 1- marker, lane 2 – nothing, lane 3 – crude extract (total cell lysate),  
lane 4 – nothing, lane 5 – flow through (proteins that do not bind to column),  
lane 6 – wash (non-specifically bound proteins), lane 7 – protein. 
2.2.4  His-Nus-tag 
The Nut Utilization Substance (Nus) is 54kDa tag.  NusA is not only efficient in 
solubilizing its fusion due to its size, but also because high levels of expression of this 
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protein occur in E. coli (11).  This tag has an N-terminally fused His-tag in the pDEST544 
vector.   
Extensive expression trials were done with the His-Nus-AofH fusion and soluble 
expression was only obtained when induced with a final concentration of 0.5mM IPTG at 
20˚C and left to express overnight.   The fusion protein was easily purified using affinity 
chromatography on a 1ml HiTrap Chelating column with the ÄKTAprime –system as can 
be seen in Figure 2.8. 
 
Figure 2.8:  The 12% SDS PAGE gel analysis of the large scale expression of His-Nus-
AofH.  Lane 1- marker, lane 2 – crude extract (total cell lysate), lane 3 –wash (non-
specifically bound proteins), lane 4 and 5 – protein. 
2.2.5  His Lumio™-tag 
Since this tag is extremely small, it was not used to obtain better solubility, but rather to 
develop a screening method.  The Lumio™ green detection system is a fluorescent base 
screen in which a FlAsH™ (Fluorescein Arsenical Hairpin binding) reagent binds site 
specifically to the tetracysteine motif Cys-Cys-Xaa-Xaa-Cys-Cys, where Xaa is any amino 
acid.  In pET160-DEST the Lumio™-tag is Cys-Cys-Pro-Gly-Cys-Cys and it binds a 
biarsenical compound that is non-fluorescent in its unbound form.  This specific tag has a 
proven higher affinity for the biarsenic compound.  In addition to the Lumio™-tag the 
plasmid also incorporates a His-tag N-terminally to the Lumio™-tag for affinity 
purification (12, 13).  The Lumio™ -AofH fusions were expressed in conjunction with the 
chaperone plasmids (section 3.1) and scarce codon coding plasmids (section 3.2) where 
the problem exists that some of the chaperone enzymes are the same size as the AofH-
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fusion and that their overexpression is much more efficient.  When expression was tried 
with this fusion no soluble protein was obtained.  
2.2.6  His-Patch Thioredoxin 
Thioredoxin is an 11.7kDa protein that is found in yeast, plants, mammals and bacteria.  
The protein was originally isolated as a hydrogen donor for ribonuclease reductase in E. 
coli and has already been completely sequenced, crystallized and its structure has been 
determined.  When used as a fusion partner, it has been known to increase translation 
efficiency and in some cases the solubility of eukaryotic proteins in E. coli (14).   
pBAD-DEST49, a plasmid we used for functional complementation studies (Chapter 3, 
section 5.1) contains the His-Patch thioredoxin (HP-thioredoxin) –tag, a slightly modified 
version of the native thioredoxin protein.  This was achieved by replacing the native Glu32 
and Glu64 residues with histidine residues.  When the protein folds the new residues at 
position 32 and 64 interact with the native histidine residue at position 8 to form a 
“patch”, from there the name His-patch.  This patch has a high affinity for divalent metal 
ions and could thus be employed in our affinity purification on the ÄKTAprime-system 
with Ni2+ (14).  
The AofH fusion was expressed from BL21* (DE3).  Unlike the plasmid used so far that 
has a T7-promoter where expression is induced with the addition of IPTG, pBAD DEST 
has the araBAD promoter (PBAD).  Expression is induced with the addition of L-arabinose.   
No soluble expression was obtained of the 66.7 kDa HP-thioredoxin-aofH fusion. 
2.2.7  Conclusion on fusion tags 
Our study towards the use of different tags to increase solubility of AofH was overall 
successful.  AofH expressed as soluble fusions to the GST-, Nus- and MBP-tags and we 
managed to purify the Nus- and MBP-tag fusions. 
2.3  Increasing solubility and translation efficiency 
Although we purified two AofH fusions successfully, we were worried that the large 
fusion partners may adversely affect the folding and activity of AofH.  In an effort to 
obtain soluble protein without the large fusion partners, we explored co-expression with 
the molecular chaperones.  Another method investigated was to increase the translation 
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efficiency of AofH by the addition of the tRNAs of the scarce codons to the translation 
mixture. 
2.3.1  Scarce codons 
This is a method to increase the translation efficiency of the target protein and hopefully 
soluble expression of AofH by the supplementation of the tRNAs of the scarce codons to 
the translation mixture.  Scarce codons refer to the codons that are not generally used by 
E. coli for expression of its native proteins.  Therefore when recombinant proteins from 
other organism are overexpressed in E. coli that need these scarce codons, problems with 
protein synthesis may occur.  Ten scarce codons were identified in AofH:  7× CGG which 
encodes arginine, 2× GGA which encodes glycine and 1×CCA which encodes proline.  
The tRNAs for these codons can be added by expressing from the Rosetta™ cell lines or 
by co-expression of the plasmids pRARE or pRARE2 (all available from Novagen).  
pRARE encodes for 6 of these scarce codon tRNAs (AUA, AGG, AGA, CUA, CCA and 
GGA) and pRARE2 for 7 (the previous 6 + CGG) (15).  Co-expression of His-AofH (form 
pET 160 EXP-aofH) and His-GST-AofH (from pET 160 GST EXP –aofH) with these two 
plasmids did not increase the solubility of the fusion.  (See next section and Figure 2.9) 
2.3.2  Chaperone plasmids 
One of the many factors that can increase the formation of inclusion bodies is misfolded 
protein (5).  So far we have tried to overcome possible misfolding by fusing AofH to 
different tags in a hope that when the tags fold correctly AofH would follow suit.  
Another possible solution is to add proteins during translation that facilitates protein 
folding.  These are known as the molecular chaperone proteins.  
The principal molecular chaperones are the heat shock proteins, Hsp70 and Hsp60, where 
70 and 60 are the sizes of the proteins in kDa.  Hsp70 is known as DnaK in E. coli.   DnaK 
functions as part of a chaperone team.  Its one co-chaperone is the 40kDa DnaJ (Hsp40).  
The other one is the nucleotide binding exchange factor, GrpE (16).  DnaK and DnaJ was 
originally identified as being necessary for bacteriophage λ DNA replication, from there 
their names (17).  These proteins are necessary in different shock states.  DnaK is 
necessary in both low and high temperature shock states, while DnaJ is only required at 
low temperatures.  GrpE is required at all temperatures (18).  To refold the protein, DnaK 
binds to the exposed, extended regions of the polypeptide which is rich in hydrophobic 
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residues, while the polypeptide is still bound to the ribosome.  This binding interaction 
keeps the polypeptide in an unfolded or partially folded configuration until enough of the 
polypeptide is synthesized for productive folding to take place, thus preventing 
premature misfolding.  Release of Hsp70 is energy dependent and occurs with the 
hydrolysis of ATP.   
The Hsp60 class is also known as chaperonins and the principal ones in E. coli are the 
GroES-GroEL complexes.  GroEL folds in a tubular shape of 15nm long and 14nm wide 
and consists of 2× 60kDa 7-membered rings stacked on top of each of each other.  The 
active site is a 5nm cavity in which ATP dependent protein refolding occurs.  The GroES 
protein is a 10kDa 7-membered ring that forms a cap on the one site of the GroEL tube.  
This complex chaperones protein folding by binding of the target protein in the central 
cavity and so preventing folding.  The protein is released by ATP hydrolysis and once 
released it can fold correctly.  The complex then moves on along the protein and binds the 
next exposed area.  The proper folding thus takes place in the short intervals during 
which the protein is released after ATP hydrolysis and before it rebinds (19). 
Tig or trigger factor, a 48kDa protein, is one of the chaperones about which little is 
known.  This chaperone is in close association with the ribosome and is involved in 
protein folding as it emerges from the ribosome.  In E. coli mutants that lack DnaK, tig is 
postulated to fulfil the role of this protein (20).  
To simplify the use of these different chaperones in protein expression, the HSP Research 
Institute has developed 5 different types of “chaperone teams” that is sold under the label 
of Takara Chaperone Plasmid Set (Refer to Table 2.5).  These sets were designed to enable 
efficient expression of molecular chaperones that are known to work in cooperation in the 
folding process (5). 
Table 2.5:  The Takara Chaperone Plasmid sets 
Plasmid Chaperones Promoter Inducer Resistant 
marker 
PG-KJE8 dnaK-dnaJ-grpE-
groES-groEL 
araB 
Pzt1 
L-arabinose 
Tetracycline 
Cloram- 
phenicol 
(Cm) 
pGro7 groES-groEL araB L-arabinose Cm 
pKJE7 dnaK-dnaJ-grpE araB L-arabinose Cm 
pG-Tf2 groES-groEL-tig Pzt1 Tetracycline Cm 
pTf16 tig araB L-arabinose Cm 
Chapter 2:  Cloning, expression and purification of AofH 
 37
We co-expressed pET160-EXP-aofH and pET160-EXP-GST-aofH with these chaperone 
teams.  The results of these expression trials are given in Figure 2.9 as the analysis of the 
lysate on 12% SDS PAGE gels.  The marker used is the Invitrogen BenchMark™ 
Fluorescent Protein Standard. 
 
Figure 2.9:  12% SDS PAGE analyses of the coexpressions of AofH fusions with the 
scarce codon plasmids and the chaperone plasmid set.  The gel on the left was 
visualized by fluorescence and the one on the right stained with Coomassie Brilliant 
Blue.  The following are in each lane:  Lane 1 is the marker; Lane 2-8 contain His- 
AofH + pRARE (lane 2) and pRARE2 (lane3), pG-Tf2 (lane4), pKJE7 (lane5), pG KJE8 
(lane6), pGRO7 (lane7) and pTf16 (lane 8).  Lane 9-13 contain His-GST-AofH + pRARE 
(lane 9), pG-Tf2 (lane10), pKJE7 (lane11), pGRO7 (lane12) and pTf16 (lane 13).   
Co-expression of pET160-EXP-aofH with pTf16 was the only one to yield soluble protein, 
as there is only one fluorescent band on the fluorescent visualized gel in Figure 2.9.  This 
corresponds to the band at 50kDa band on the stained gel in lane 8.  Large-scale 
expression and purification of the AofH fusion was attempted on the ÄKTAprime-system, 
without success.  The 12% SDS PAGE gels confirmed that overexpression of the proteins 
had occurred and bands of the right sizes were present in the flow through and non-
specifically bound protein wash samples (Figure 2.10, lanes 2-6).   
In the stained gel in Figure 2.9 in lane 11 there is a thick band at more or less 76kDa, the 
size of His-GST-AofH.  The band was not visible on the fluorescent gel, but this may be 
caused by steric interferences of the GST-tag that may interfere with the binding of the 
FlAsH™ reagent or the protein may be denatured.  Large-scale co-expression and 
purification of this fusion protein with plasmid pKJE7 was attempted.  As can be seen in 
Figure 2.10 in lane 7 the protein expressed well, but we did not manage to purify it with 
affinity chromatography.  Closer inspection revealed that this band, which we identified 
as His-GST-AofH, may also be one of the chaperones, DnaK.  
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Figure 2.10:  The 12% SDS PAGE gel of the purifications attempted of His-AofH and 
His-GST-AofH obtained with coexpressions with the chaperone plasmids.  The lanes 
contain the following samples:  Lane 1-marker, lane 2 – His-AofH crude extract (total 
cell lysate), lane 3 – His-AofH flow through, lane 4 – His-AofH non-specifically bound 
protein wash peak, lane 5 – where is the purified protein? lane 6 - purified protein, 
lane 7 – GST-AofH crude extract which we suspect is the chaperone GroEL. 
The purification of His-AofH co-expressed with Tig was tried using different purification 
conditions.  The cells were lysed with Novagen Bugbuster™ Protein Extraction Reagent (a 
detergent mix that perforates the cell walls of the host without denaturing the proteins it 
liberates) instead of with sonication.  Purification on the ÄKTAprime-system was tried on 
the Amersham columns and the Sigma Ni2+ NTA columns with His-select binding buffer 
and His-select elution buffer (refer to Table 2.3 for buffer composition).  When no 
purification was obtained under these conditions, gradient elution was attempted by 
raising the imidazole concentration from 10mM to 46mM over a period of 10 minutes.  All 
the fractions that may contain the purified protein were pooled and concentrated with a 
SIGMA® IVSS 20 VIVASPIN centrifugal concentrator.  This method also proved to be 
unsuccessful.  The conclusion was reached from the SDS PAGE analysis that His-AofH 
doesn’t bind to any of the columns (Figure 2.11).  One of the factors that may cause this is 
N-terminal masking of the His-tag due to the anionic nature of AofH.  However, this 
possibility has not yet been investigated further.  
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Figure 2.11:  Second round of purification of His-AofH co-expressed with Tig.  The 
cells were lysed with Bugbuster™ reagent instead of the normal sonication.  The lanes 
contains the following samples:  Lane 1 – marker, lane 2 – crude extract (total cell 
lysate), lane 3 – flow through of the Sigma Ni2+ NTA column, lane 4 – flow through of 
the Amersham column, lane 5 – wash peak, lane 6 – flow through obtained of the re-
injected wash peak, lane 7 – flow through of the concentrator, lane 8 – the 
concentrated protein. 
2.4  Other expression methods 
2.4.1  Expression from yeast 
Due to the slight expression problems we experienced of native AofH from the E. coli 
system, we also tried expression from a yeast system.  We used the ura- yeast strain Y294 
and aofH was subcloned into the GATEWAY™ plasmid pYES-DEST52.  As in the case of 
pBAD-DEST49, expression is induced by L-arabinose due to the GAL1 promoter.  No 
expression was detected with SDS PAGE analysis.  It only came under our attention much 
later that yeast expression levels from a plasmid is typically very low and the protein 
cannot necessarily be visualized with SDS PAGE.  In the future Western blot analysis 
should rather be used. 
2.5  Protein refolding  
The literature defines insoluble expression as the accumulation of the target protein in 
insoluble inclusion bodies when expressed from the E. coli system.  One of the methods 
described to bridge this problem that hasn’t been discussed so far, is protein refolding.  
Normally the insoluble inclusion bodies are isolated by centrifugation followed by 
solubilization under denaturing conditions.  The protein is then dialyzed or diluted into a 
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non-denaturing buffer where proper folding occurs to yield a soluble protein.  Some of 
the methods used include single step dialysis/diafiltration, multi-step dialysis, single-step 
dilution, gel filtration, immobilization assisted refolding and refolding with a detergent 
and cyclodextrin (21).  We tried two different methods to solubilize AofH. 
2.5.1  Method 1:  Artificial chaperone chemical-assisted method 
The first method we tried is the “artificial chaperone chemical-assisted” method.  This 
method is a hybrid between the last two methods mentioned in the previous paragraph 
and dilution into a non-denaturing buffer.  The immobilization assisted refolding method 
requires that the target protein binds to an insoluble matrix, usually by the use of an 
affinity tag.  The advantages of this system are that aggregation is minimized due to 
spatial separation of the bound proteins and that the refolded proteins can be eluted at 
relatively high concentrations.  Refolding with detergent and cyclodextrin mimics the role 
of the chaperonins GroEL-GroES in protein refolding.  The detergent prevents 
aggregation and the cyclodextrin strips away the detergent (21).  The refolding of AofH 
on a column was attempted with minor modifications according to a method described by 
Oganesyam et al. (8) 
His-AofH was overexpressed and purification attempted with the ÄKTAprime-system 
using an Amersham HiTrap chelating column and the peaks obtained analyzed on 12% 
SDS PAGE gels.  Once again the chelating problem was encountered since the protein was 
present in the crude extract sample and in the flow through, but nowhere else.  (Refer to 
Figure 2.12)  To increase the binding efficiency the flow rate from the injection onwards 
was decreased from 1.0ml.min-1 to 0.1ml.min-1, but this made no difference. 
2.5.2  Method 2:  Dilution into non-denaturing buffer 
The second refolding method attempted was dilution of the ureum treated protein into a 
large volume of non-denaturing buffer.  The refolding was tried according to the method 
described by Witt et al. (22) with minor modifications.  The solubilized inclusion bodies 
were diluted into 50Х their volume of renaturing buffer and left at 4˚C to refold with mild 
stirring.  After the refolding process was completed, the enzymatic mixture was 
concentrated and purified on an Amersham 5ml HiPrep™ 16/10 DEAE FF column and 
gel filtered.  The refolded protein was used in assays to determine if FAD was 
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incorporated during the refolding (see Chapter 3, section 6.3).  According to these scans 
this procedure was also unsuccessful. 
 
Figure 2.12:  Attempts at refolding and purifying His-AofH according to the artificial 
chaperone chemical-assisted method.  The samples in the lanes are as follows:  
Lane 1 – marker, lane 2 – protein crude extract in denaturing buffer, lane 3 – flow 
through, lane 4 – non-specifically bound proteins, lane5 – sample that should contain 
protein.  
2.6  Conclusion 
Problems were experienced with the soluble expression and purification of AofH.  To 
overcome this problem various techniques were investigated.  One of these methods is the 
fusion of AofH to various fusion tags, which include the GST-, His-GST-, His-Lumio™-, 
His-GST-Lumio™ -, MBP- and Nus-tags.  Soluble protein expression was obtained for all 
the fusions with the exception of the His-tag.  The other methods used to increase 
solubility and expression were co-expression of the Lumio™-AofH fusions with the 
chaperone proteins, addition of the scarce codon tRNA’s to the translation mixture and 
protein refolding.  Of these methods only His-Lumio™-AofH co-expressed with the 
trigger factor, Tig, expressed solubly.  We purified the Nus- and MBP-tag AofH fusions.  
These proteins were used in further applications to determine the activity of AofH. 
2.7  Experimental 
All ÄKTAprime columns except the Ni2+ NTA columns were from Amersham Biosciences 
and purchased from either Amersham or Sigma-Aldrich.  The Ni2+ NTA columns, FAD 
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and IPTG were from Sigma-Aldrich.  The Novagen Bugbuster™ Protein Extraction 
Reagent and most of the buffer components were purchased from Merck.  The enzymes 
were purchased from Fermentas, Promega or New England Biolabs.    Mycobacterium 
tuberculosis genomic DNA was a gift from Rob Warren from Medical biochemistry at 
Tygerberg campus, University of Stellenbosch (US).  The plasmids pDEST544 and 
pDEST566 were kind gifts from Dr Cynthia Kinsland from Cornell University, USA.   
2.7.1  DNA amplification 
The aofH-gene was amplified from genomic DNA of Mtb strain H37Rv with the forward 
primer 5’-CTGTACTTCCAGCATATGACAAACCCACCGTGG-3’ which introduced an 
NdeI (underlined) restriction enzyme site.  The reverse primer was 5’-
GAAAGCTGGGTGCTCGAGCTCATAGCAGGGCGG-3’ and introduced an XhoI-site 
(underlined).  The primers used were designed according to Gateway™ technology, 
which includes a universal sequence to introduce the attB sites before and after the target 
sequence.  This allows BP-reactions with the pDONR-vectors to yield the necessary entry-
vectors to create the expression vectors, although in this case the classic restriction digest 
and ligations were used to obtain the entry-vectors (discussed later).  For amplification 
AMP-buffer was used with 0.4mM dNTP mix, 1mM forward primer, 1mM reverse 
primer, 2ng genomic DNA, varied MgSO4 concentrations, 1.25U Pfu and distilled, 
deionized water (ddH2O) to a final volume of 25µl.  The PCR program had an initial step 
of 2 min at 95˚C followed by denaturation for 15s at 94˚C, annealing for 30s at 55˚C and a 
polymerization step of 1min at 68˚C.  This was repeated for 30 cycles and the program 
ended with a hold step at 4˚C.  The reaction mixtures were analyzed by gel 
electrophoresis on a 1% agarose gel and the bands visualized by staining with SYBR®gold 
and viewed on a Darkreader.  Product bands at 1 347bp were obtained at MgSO4 
concentrations of 2, 3 and 3.5µM. and were purified from the gel with a GFX PCR DNA 
and Gel band purification kit. 
2.7.2  Restriction Digestions 
The aofH PCR product, pET28a(+) and pENTR4N were digested with NdeI and XhoI.  The 
digestions were carried out at 37˚C in Promega buffer D, 0.1mg.ml-1 BSA, 14µl PCR 
product/plasmid, 20U NdeI, 20U XhoI and ddH2O to a final volume of 20µl.  When the 
digestion was completed, the mixtures were purified on 1% agarose gels and the bands of 
the correct size purified form the gel with a GFX PCR DNA and Gel band purification kit. 
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2.7.3  Construction of plasmids 
Two methods were used to construct the plasmids in this study.  The first involved the 
use of restriction digestions (as described above), followed by ligation and screening.  In 
the second method the LR reaction of the GATEWAY™ system was used.   
2.7.3.1  Method 1 - Ligation and screening 
Equal amounts of the already digested plasmid and PCR product were added together in 
a final volume of 9µl and incubated at 45˚C for 5 min.  This was followed by a cooling 
period on ice for 10min after which T4 ligase buffer and 2U T4 DNA ligase (Promega) 
were added to give a final volume of 10µl and the mixture incubated at 20˚C for 4 hours.  
The entire reaction mixture was transformed into DH5α (or Mach1) and plated on Luria 
Bertani (LB) plates enriched with 30mg.ml-1 kanamycin and incubated overnight at 37˚C.  
Colonies obtained were screened by adding a smear of each colony to 25µl Epilyse 
solution 1 (30mM Tris-HCl, pH 8.0, 5mM Na2EDTA, 50mM NaCl, 20% sucrose, 
0.047µg.ml-1 lysozyme and 0.047µg.ml-1 RNAse) and mixing.  After 10µl Epilyse solution 2 
(1×TAE, 2% SDS, 5% sucrose and 2mg.ml-1 bromophenol blue) was added, the mixtures 
were analyzed on 1% agarose gels by comparing the samples to the undigested parent 
plasmid.  DNA-samples that were larger than the original plasmid were subjected to 
further screening.  This involved purification of the target plasmids from overnight 
cultures by making use of Eppendorf purification kits.  For each new plasmid restriction 
enzyme(s) was identified that yields a unique restriction pattern.  The digested plasmids 
were analyzed on 1% agarose gel.  If the desired pattern was obtained, the plasmid was 
stocked and used in further applications. 
2.7.3.2  Method 2 – Gateway™ LR reaction 
This system allows the formation of expression clones by adding together an entry 
plasmid (pENTR) containing the gene sequence and a destination plasmid (pDEST) 
together with LR clonase.  Both plasmids contain defined att-sites.  During the LR reaction 
the fragments of DNA between the att-sites get exchanged.  This allows the formation of 
an expression vector containing the target DNA sequence.  The advantages of this system 
are that restriction digest are only used in the creation of the entry plasmid and that the 
plasmids are designed to eliminate false positives.  This is obtained by the ccdB– suicide 
gene sequence that are contained within the cassette (the area between the two att-sites 
that are exchanged during the LR reaction) and the ampicillin resistance of the destination 
Chapter 2:  Cloning, expression and purification of AofH 
 44
plasmids as opposed to the kanamycin resistance of the entry plasmids.  If the exchange 
reaction failed, the colonies containing destination plasmid would die due to the suicide 
gene and the entry vector due to the antibiotic selection. 
The destination plasmid (pDEST) and an entry plasmid (pENTR) were added together in 
a ratio of 3:1 with 1µl LR clonase buffer and 1µl LR clonase (final volume: 5µl) and 
incubated at 25˚C.  The reactions were terminated by addition of 1µl of Proteinase K and 
incubation for a further 10min at 37˚C.  Part of or the entire LR-mixture was transformed 
into DH5α or the Mach1 cell strain, plated on LB plates enriched with 100mg.l-1 ampicillin 
and incubated overnight at 37˚C.  Any colonies found the next day were screened in two 
different ways.  The first round of screening entails streaking each colony on 2 different 
LB reporter plates, one enriched with 100mg.l-1 ampicillin and the other with 25mg.l-1 
chloramphenicol.  The colonies that contain the correct construct would grow on the 
ampicillin enriched plate, but not on those enriched with chloramphenicol.  The second 
round of screening is a digestion with an enzyme that yields a unique digestion pattern.  
For most of the expression clones this enzyme was BsrGI, a restriction enzyme that digests 
only within the att-sites of the expression clones if the exchange occurred correctly.  For 
the digestions 20U of BsrGI in NEB buffer, BSA and ddH2O in a final volume of 20µl was 
used.  The digested plasmid was analyzed on 1% agarose gel, stained with SYBR®gold 
and visualized with the Darkreader.   If only two bands were found of which one is more 
or less the size of the insert, the construct was correct and could be used in further 
applications. 
2.7.3.3  The constructed plasmids 
2.7.3.3.1  pENTR4N-aofH  
This plasmid was constructed according to method 1 by adding 35fmoles of pENTR4N to 
aofH PCR product, both digested with NdeI and XhoI.  The ligation mixture was 
transformed into DH5α.  The unique cutter enzyme used was PfiMI which has a single 
restriction site in pENTR4N, but two in pENTR4N-aofH.  Restriction digestion yields two 
bands of 2 141bp and 1 494bp.  The reaction was done in Fermentas buffer R+ (10mM Tris-
HCl, pH8.5, 10mM MgCl2, 100mM KCl, 0.1mg.ml-1 BSA) with 10U of enzyme.  
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2.7.3.3.2  pET28a-aofH 
The aofH plasmid sequence was cut from pENTR4N-aofH using Promega buffer D, BSA, 
20U NdeI, 20U XhoI and ddH2O in a final volume of 20µl.   The digestion mixture was 
separated on a 1% agarose gel, visualized with SYBR®gold on the Darkreader and the 
correct band purified from the gel with a GFX PCR DNA and Gel band purification kit.  
23fmoles of each was ligated and transformed into DH5α.  Overnight cultures were made 
of the colonies that might contain the right plasmid, the plasmid purified and digested 
with 20U Bpu1102I in buffer Y+/Tango and ddH2O till 20µl at 37˚C for 3.5 hours. 
2.7.3.3.3  pEXP15-aofH 
Ms. Leisl Brand created this plasmid by combining the Gateway plasmid pDEST15 with 
pENTR4N-aofH according to method 2.  40ng of pDEST15 and 30ng of pENTR4N-aofH 
were reacted with LR clonase at 25˚C for 2hours and 40 min. 
2.7.3.3.4  pEXP566-aofH 
This plasmid was created as described by method 2 by adding 60ng of pDEST566 to 15ng 
of pENTR4N-aofH.  The LR reaction was left at 25˚C for 4hours and 45 min before 
transforming the entire mixture into Top10 DH5α. 
2.7.3.3.5  pEXP544-aofH 
48ng pDEST544 was combined with 60ng pENTR4N-aofH using method 2. 
2.7.3.3.6  pET160-EXP-aofH 
This plasmid was made by Ms. Leisl Brand.  75ng of pET160-DEST and 30ng of 
pENTR4N-aofH was reacted with LR clonase at 25˚C for 2hours and 40 min. 
2.7.3.3.7  pET160-GST-EXP-aofH 
Combine 48ng pET160-GST-DEST with 60ng pENTR4N-aofH using the technique 
described in method 2.  Transformation mixtures were transformed into Mach1. 
2.7.3.3.8  pBAD-EXP49-aofH 
Using method 2, 75ng pBAD-DEST49 was combined with 30ng pENTR4N-aofH.  
Transformation mixtures were transformed into Mach1. 
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2.7.3.3.9  pYES-EXP52-aofH 
Once again method 2 was employed.  To increase the efficiency of the LR-reaction with 
pYES-DEST52, 600ng plasmid was first linearized by digesting with 24U of EcoR1 in 
Promega Buffer H, BSA and ddH2O at 37˚C for 2 hours.  The mixture was loaded on a 1% 
agarose gel, stained with SYBR®gold and visualized on the Darkreader.  The linearized 
plasmid was purified from the gel using the Eppendorf gel band purification kit.  19ng 
pYES-DEST52 was incubated with 60ng pENTR4N-aofH and LR clonase for just short of 
24 hours before adding Proteinase K.  The transformation mixture was transformed into 
Mach1.  Positive results were obtained with the antibiotic screen, but could not be 
confirmed by restriction digestions with BsrGI.  The restriction pattern obtained from the 
parental plasmid gave bands at 5 607, 1 310, 403 and 302bp while the constructed plasmid 
have band at 5 607, 1 397 and 302bp.  To confirm the construct, restriction digests were 
done with NdeI and XhoI to cut out the target sequence.  NdeI is a single cutter of pYES-
DEST52 and the plasmid has no XhoI-site.  The digestion was carried out in buffer R+ with 
20U of NdeI, 20U of XhoI, 7µl of template and ddH2O to a final volume of 20µl, incubated 
at 37˚C for 3 and half hours and analyzed on 1% agarose gel.   
2.7.4  Overexpression and purification methodology: 
All the plasmids were first subjected to expression trials to determine the correct 
parameters for soluble expression of the target protein.  When the optimum set of 
parameters were determined, the tagged protein was overexpressed on large scale and 
purification attempted.   
2.7.4.1  Expression trails 
The appropriate plasmids were transformed into a suitable E. coli strain (BL21 (DE3), 
BL21*(DE3) or Tuner (DE3)) for expression.   For the expression trials 15ml LB media 
containing the correct antibiotic was inoculated with overnight culture.  These were 
incubated at 37°C and 200rpm (vigorous) shaking until an OD600 of more or less 0.6 (mid-
log-phase growth) was reached.  Each experiment was then induced with a 
predetermined amount of isopropyl-β-D-thiogalactoside (IPTG).  The solubility of the 
target protein was tested by varying the following parameters at which expression occurs 
after induction:   
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1. IPTG concentration (final concentration = 1mM, 0.75mM, 0.5mM, 0.2mM, 0.1mM or 
0.05mM)  
2. Period of incubation after induction (2h, 4h or overnight) 
3. Temperature at which induction occurs  (15˚C, 20˚C, 25˚C, 30˚C or 37˚C) 
After the incubation period elapsed, the culture was harvested by centrifugation at 
4500rpm for 30min at 4°C.  The pellet was stored at -20° C till use.   
2.7.4.2  Large scale expression 
LB (normally 500ml) containing the correct amount of the specific antibiotic was 
inoculated with overnight culture of the plasmid containing E. coli expression strain.  The 
inoculated media was incubated at 37°C and 200rpm shaking till OD600 = 0.6 before 
induction with IPTG and expression was continued in accordance with the other 
predetermined parameters.  When the time for expression had elapsed, the cells were 
harvested by centrifugation at 4500rpm for 30min at 4°C and the pellet stored at -20° C till 
use.   
2.7.4.3  Purification of expression trials to analyze soluble and insoluble proteins 
The pellets harvested from the 15ml cultures were resuspended in 2ml binding buffer 
(10mM Tris-HCl, pH 8.0) and 200µl aliquots taken and pelleted again.  To evaluate the cell 
free extracts (i.e. the soluble proteins), the pellets were resuspended in 100µl elution 
buffer and glass beads added equal to half the volume of the suspended pellet.  The 
mixture was vortexed for 10min to break open the cells and centrifuged at 13 000rpm for 
2min to collect the cell debris.  A sample of the supernatant was used to analyze the 
proteins on SDS PAGE gels (as described below).  For whole cell samples (to analyze the 
total protein content of the cell lysate) the original pellet was resuspended in 50µl elution 
buffer and taken as is for SDS PAGE analyses.   
2.7.4.4  Purification of protein obtained in large scale expressions 
The pellet was resuspended in a volume of 10× the pellet weight of binding buffer (20mM 
Tris-HCl, 5mM Imidazole, 500mM NaCl, pH 7.0) and cooled down to below 10°C.  Cells 
were disrupted by sonication and the cell debris was collected by centrifugation at 
15 000rpm for 30min at 4°C.  To prepare the supernatant for purification it was filtered 
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using CAMEO 25AS acetate filters with a pore size of 0.45micron after which it was 
injected into the ÄKTAprime -system.   
For purification of the His-tag fusions the following general procedure was followed.  The 
tag-containing protein was loaded on a 1ml Amersham Biosciences HiTrap Chelating HP 
column that was preloaded with Ni2+.  After a wash step (15% elution buffer, 85% binding 
buffer) to remove any non-specific bound proteins from the column, the target protein 
was eluded by increasing the imidazole, a structural analog of histidine, concentration in 
the buffer (20mM Tris-HCl, 500mM NaCl, 50mM imidazole, pH 7.9).  The elution was 
monitored by UV at 280nm.  After elution all protein samples were desalted (also on the 
ÄKTAprime-system) using an Amersham Biosciences 5ml HiTrap desalting column and 
gel filtration buffer (25mM Tris-HCl, 5mM MgCl2, 5% glycerol, pH 8.0) 
2.7.4.5  Analysis on 12% SDS PAGE gels 
The proteins were visualized by using 12% SDS PAGE gel electrophoresis.  A sample of 
the appropriate volume was mixed with an equal volume of 2× SDS-PAGE loading buffer 
(0.125M Tris.-HCl, pH 6.8, 4% SDS, 30% glycerol, 1.5% β-mercaptoethanol and 0.02 % 
bromophenol blue) and boiled at 95°C for 5min after which the samples were loaded on 
the gel and ran in 1× SDS-PAGE running buffer (0.1% SDS, 0.025M Tris and 0.192M 
glycine).  The standard experiment comprised of at least four samples, the purified 
protein and as references the crude extract from the bacterial lysate, the flow through 
(proteins that did not coordinate to the Ni2+) and the wash peak (proteins that bound non-
specifically to the column).  After the run was completed the gel was stained with 
Coomassie blue stain (45ml MeOH, 40ml ddH2O, 10ml CH3COOH and 250mg Coomassie 
Brilliant Blue) for 30min and destained with destaining solution (45% MeOH, 45% ddH2O, 
10% CH3COOH) for 2 hours. 
2.7.4.6  Determination of protein concentration 
The concentration was determined with the Bradford method using bovine serum 
albumin (BSA) standards.  To determine the protein concentration a dye, Coomassie 
Brilliant Blue, was added to the protein samples.  This dye has absorption maxima 
between 470 and 650nm in its free form, but bound to a protein the absorption maxima 
shifts to 595nm (23).  Bovine serum albumin standards (Biorad) of known concentrations 
were used to plot a standard curve of absorbance versus concentration using the Thermo 
Varioskan™ and Skanit software version 2.2.1.  This curve was then used to determine the 
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concentration of the target protein of which the absorbance was measured.   For each new 
protein concentration determination a new standard curve was constructed. 
2.7.5  Overexpression and purification used in this study. 
2.7.5.1  His-GST 
For large scale overexpression 500ml cultures were induced at OD600 = 0.6 with a final 
concentration of 0.1mM IPTG at 37˚C and left overnight.  The harvested cells were 
disrupted by sonication and the lysate filtered with a 0.45-micron acetate filter.  The lysate 
was purified by affinity chromatography with a 1ml HiTrap Chelating HP column on the 
ÄKTAprime-system. 
When this purification method proved unsuccessful, different buffers were investigated 
for purification.  The compositions of the different buffers are described in Table 2.3 and 
the combination used given in Table 2.4. 
All experiments were based on the small-scale batch method described in the Novagen 
His-Bind® Kits instruction manual (24).  After expression, 0.5g of pellet was resuspended 
in 2.5ml room temperature Novagen Bugbuster™ Protein Extraction Reagent and 
incubated at room temperature with mild shaking for 30min.  To pellet the cell debris the 
suspension was centrifuged at 15 000rpm for 30min at 4°C and the protein containing 
supernatant extracted.   
Batch purifications were performed in 1.5ml Eppendorf tubes to which 100µl high density 
IDA-agarose 6 BCL Ni2+ charged resin (Agarose Beads technology) was added to give a 
bed volume of 50µl.  The resin was washed 2× with 100µl sterile ddH2O and 2× with 100µl 
of the appropriate binding buffer.  The washing was accomplished by adding the liquid, 
inverting the tubes a few times and then spinning at 8 000rpm for 1min at room 
temperature.  Protein containing supernatant (100µl) was added to the washed Ni2+-
charged agarose and the mixture was incubated with mild shaking at room temperature 
for 5min.  The agarose was spun down and the eluant removed (flow through sample).  
The agarose-protein fractions were washed 1× with 100µl binding buffer and 2× with 
150µl binding buffer.  The protein was eluted with 150µl elution buffer.  Aliquots of the 
flow through, the wash and eluted protein were analyzed on 12% SDS PAGE gels. 
For manual purification a column made in a plastic Pasteur pipette and a bed volume of 
1ml Ni2+ NTA resin was used.  The resin was equilibrated by washing 2× with 2 CV sterile 
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ddH2O and 2× with 2 CV PBS-buffer.   5ml protein crude extract was loaded on column 
and washed 3× with 3 CV PBS buffer.  To elute any non-specifically bound protein the 
column was eluted 2× with 3 CV PBS buffer mixed with 15% elution buffer (His-select 
EB).  This was followed by elution 2× with 3 CV 100% elution buffer.  300µl fractions were 
taken in a microtiter plate and scanned at 280nm.   
2.7.5.2  MBP-tag 
One round of expression trials were performed in BL21* (DE3) and soluble protein was 
obtained.  For large-scale expression 1litre cultures were induced with a final 
concentration of 0.2mM IPTG at 37˚C and grown for 3hours.    
2.7.5.3  Nus-tag 
Expression trials were done at 15°C, 20°C, 25°C, 30°C and 37°C for 2h, 4h and overnight in 
BL21* (DE3) and by varying IPTG concentration in Tuner (DE3).  AofH expressed solubly 
only when induced with a final concentration of 0.5mM IPTG at 20˚C and the expression 
was left overnight.  
2.7.5.4  Lumio™-tag 
All the expressions with this plasmid were on small scale by growing the plasmid 
containing BL21*(DE3) cultures in LB media supplemented with 100mg.l-1 ampicillin 
(selection for pET160-EXP-aofH) and 20 mg.l-1 chloramphenicol (selection for the 
chaperone and scarce codon plasmids) till an OD600 = 0.6.  The cultures were induced with 
a final concentration of 0.5mM IPTG at 37˚C and grown for 3 hours at 37˚C and 200rpm 
after which the pellets were harvested by centrifugation at 4500rpm for 30min at 4˚C.  The 
pellets were redissolved in lysis solution (50mM potassium phosphate buffer, pH 7.8, 
400mM NaCl, 100mM KCl, 10% glycerol, 0.5% Triton X-100, 10mM imidazole) and 15µl 
aliquots were taken to analyze the protein content of the lysate and to determine which 
proteins are soluble and insoluble.  The aliquot to determine the protein content was 
analyzed as is while the other sample was pelleted.  The supernatant was analyzed for the 
soluble proteins and the pellet for the insoluble proteins.  The pellet was resuspended in 
50µl 8M urea and a 15µl aliquot used.  To all three samples 5µl 4× LumioTM Gel sample 
buffer and 0.2µl Lumio™ Green detection reagent was added before incubating at 70˚C 
for 10min.  After cooling down and spinning to collect, 2µl Lumio™ In-Gel Enhancer was 
Chapter 2:  Cloning, expression and purification of AofH 
 51
added, the samples mixed and incubated at room temperature for 5 minutes.  The 
samples were analyzed on a 12% SDS-PAGE gel (12, 25). 
2.7.5.5  His-Patch Thioredoxin 
This AofH fusion was expressed from BL21*(DE3).  The cultures were grown at 37˚C with 
200rpm shaking till an OD600 = 0.6 after which it was induced with different amounts of  
L-arabinose (final concentrations: 0.2%, 0.02%, 0.002% 0.0002% and 0.00002%) and grown 
further at 37˚C and 200rpm shaking for another 3 hours.  The cells were harvested by 
centrifugation at 4 500rpm for 30min at 4˚C.  The pellets were redissolved in Lumio™ 
lysis solution (as described in section 2.7.5.4) and the supernatant (soluble proteins) 
analyzed on a 12% SDS PAGE gel.  
2.7.5.6  Scarce codons 
pRARE or pRARE2 was transformed into competent BL21*(DE3) and plated on LB plates 
with 20mg.l-1 chloramphenicol.   Colonies of both plasmid containing cells were used to 
make competent cells from.  pET160-EXP-aofH was transformed into both and pET160-
EXP-GST–aofH only into the competent cells that contained pRARE.  These 
transformations were plated on LB plates that containing 20mg.l-1 chloramphenicol and 
100mg.l-1 ampicillin.  We did the expression trials for the pET160-EXP-aofH cultures on 
15ml scale by growing at 37˚C and 200rpm shaking till an OD600 = 0.79 and inducing with 
a final concentration of 0.46mM IPTG.  The cultures were grown for a further 3 hours at 
the same conditions.  The cells were harvested by centrifugation at 4 500rpm for 30 min at 
4˚C. 
2.7.5.7  Chaperone plasmids 
The expressions trials were performed in the same manner as in section 2.7.5.6.  The 
expression of pET160-EXP-aofH was done in 1.5ml LB containing 20mg.l-1 
chloramphenicol and 100mg.l-1 ampicillin.  All the pET160-EXP-GST-aofH combinations 
were expressed using auto-induction media.  The cells are harvested by centrifugation at  
4 500rpm for 30min at 4˚C and the soluble and insoluble proteins were analyzed using the 
Lumio™ detection method (as described in section 2.7.5.4). 
2.7.5.8  Alternative expression methods for GST-tag fusions (7) 
Six tubes for small-scale expressions were inoculated.  This was grown till an OD600 = 0.68 
(literature: 0.7) at 37˚C with shaking at 200rpm.  After this the temperature was reduced 
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till 25˚C and grown till an OD600 = 1.28 (literature 1.2) and then at 18˚C at 200rpm till an 
OD600 = 1.5.  The expressions are induced with IPTG (final concentrations: 1, 0.75, 0.5, 0.2, 
0.1, 0.05mM) and allowed to grow overnight at 18˚C and shaking at 200rpm.  The cells 
were harvested with centrifugation, broken with glass beads and the soluble proteins and 
whole cell sample analyzed with SDS PAGE gel electrophoresis. 
2.7.5.9  Protein Refolding 
2.7.5.9.1  Method 1:  Artificial chaperone chemical-assisted method 
The bacterial cell pellet was lysed with sonication and the inclusion bodies pelleted by 
centrifugation at 15 000rpm for 30 min.  Inclusion bodies were dissolved in denaturing 
buffer (Table 2.6) and filtered through a 0.45micron CAMEO acetate filter.  For the 
refolding and purification six different buffers were used as described in Table 2.6.  The 
sample was injected into the ÄKTAprime-system on a 1ml Amersham column and washed 
with denaturing buffer.  This was followed by a wash step with 10× CV of detergent 
buffer and another wash with 10× CV of buffer containing β-cyclodextrin.  Before elution 
the column was washed with wash buffer to remove the β-cyclodextrin.  The protein was 
eluted with elution buffer and the fractions obtained were on a 12% SDS PAGE gel. 
Table 2.6:  Buffers used for artificial chaperone chemical-assisted AofH refolding 
Buffer Composition Remark 
Buffer A 
20mM Tris-HCl 
100mM NaCl 
10mM β-mercaptoethanol 
pH 6.7 
pH is dependent of pI of target protein.  
AofH pI was taken form Tuberculist. 
β-mercaptoethanol is added to cleave 
possible cysteine bonds 
Denaturing buffer Buffer A 8 M urea 
Solubilization of target protein in 
inclusion bodies 
Detergent buffer Buffer A 0.1% Triton X-100 
Detergent minimizes hydrophobic 
interactions between aliphatic and 
aromatic residues. 
Refolding buffer 
Buffer A 
5mM β-cyclodextrin 
0.05mM FAD (22) 
β-cyclodextrin removes the detergent.  
Since AofH is expected to be a flavin 
dependent protein, FAD is needed for 
correct folding. 
Wash buffer 
20mM Tris-HCl 
0.5mM NaCl 
10mM β-mercaptoethanol 
pH 6.7 
Removes β-cyclodextrin 
Elution buffer 
Buffer A 
600mM imidazole 
pH 8 
Elute target protein 
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2.7.5.9.2  Method 2: Dilution into non-denaturing buffer 
Protein refolding was done according to the method described by Witt et al. (22) with 
minor modifications.  The bacterial cell pellet was lysed with sonication and the inclusion 
bodies pelleted by centrifugation at 15 000rpm for 30 min.  The inclusion bodies were 
washed once with wash buffer (10mMTris.HCl, 1mM EDTA, 0.8% NaCl, pH 7.76) 
excluding and once with wash buffer including 0.1% Triton X-100.  After the wash step 
the inclusion bodies were solubilized in denaturing buffer (8M urea, 50mM DTT) and 
kept on ice for 60min.  The debris was pelleted by centrifugation and the protein 
concentration of the supernatant determined with the Bradford reagent and BSA protein 
standards as 4.6 mg.ml-1.  The supernatant was diluted 50× in renaturing buffer (20mM 
Tris. HCl, pH 7.6, 10% (v/v) glycerol and 0.05% FAD) and stirred very slowly at 4˚C for 1 
week.  For the concentration of the protein sample a SIGMA® IVSS 20 VIVASPIN 
centrifugal concentrators were used and the protein purified on the ÄKTAprime-system 
with an Amersham 5ml HiPrep™ 16/10 DEAE FF column.  The protein was eluted by 
gradient elution from buffer A (20mM Tris.HCl, pH 7.5) to buffer B (20mM Tris.HCl, pH 
7.5, 1M NaCl). 
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C h a p t e r  3  
Activity of AofH: 
Identification of products of the enzymatic reactions and confirmation of the presence of 
FAD and H2O2 
3.1  Introduction 
With pure AofH in hand (obtained as described in chapter 2) we set out to determine the 
activity of the protein.  Based on sequence homology to the yeast protein Fms1 AofH 
should be a polyamine oxidase which produces 3-aminopropanal as a product of one of 
its reactions.  The various reactions of Fms1 with different polyamines are summarized in 
Figure 3.1.   
 
Figure 3.1:  PAO reactions based on the reactivity of Fms1.  Although spermidine is 
not a substrate of Fms1 it may still be a substrate of AofH. 
Fms1 oxidizes spermine (spm) and N1-acetylspermine (N1-spm) to spermidine (spd) and 
an aldehyde, which is 3-aminopropanal in the case of spm and N-acetyl-3-aminopropanal 
in the case of N1-spm.  N8-acetylspermidine (N8-spd), unlike the previous substrates that 
H2N NH
H
N NH2 H2N OH2N NH
NH2 +
3-aminopropanalSpermine
N1-acetylspermine
N
H
N
H
H
N NH2 N
H
O
+
O O
Spermidine
N8-acetylspermidine di-aminopropane
H2N NH
H
N
N
H
H2N NH2 +
O
O
O
+ H2N
NH2
Putrescine
PAO
H2N NH
NH2
Spermidine
H2N NH
NH2
Spermidine
PAO
PAO
PAO
H2N O
3-aminopropanal
Chapter 3: Activity of AofH 
 57
are oxidized on the three carbon side of the secondary amine, is oxidized on the four 
carbon side of the secondary amine.  The products obtained from this reaction are 
diaminopropane and N-acetylbutanal.  Spermidine is not a substrate of Fms1, but this 
does not discount it from being a PAO substrate.  Should it be oxidized the expected 
products would be either 3-aminopropanal and putrescine or 3-aminobutanal and 
diaminopropane. 
The products formed with the enzymatic reactions were analyzed with various direct and 
indirect methods.  The first method used was thin layer chromatography (TLC).  In this 
method a small aliquot of the sample (≈5µl) is applied to a silica plate where it was 
subsequently resolved by a predetermined eluant.  The second method used was reverse 
phase high performance liquid chromatography (HPLC).  In this method the sample was 
injected onto a non-polar C18 column and separated by a polar mobile phase(s).  Samples 
for analyses were prepared by derivatization of the enzymatic reactions mixtures with 
fluorescent molecules.  This allows for more sensitive detection. 
A more direct method of determining the specific products is electrospray mass 
spectroscopy (ESI-MS) and liquid chromatography mass spectroscopy (LC-MS).  In these 
techniques the molecules are analyzed by mass (1).  The major difference between these 
techniques is that in LC-MS the reaction mixtures are first resolved with HPLC prior to 
the MS analysis.  For analysis the enzymatic mixture had to be diluted to product 
concentrations of 10µg.ml-1 in 50% ACN and ddH2O.  In ESI-MS analysis the enzymatic 
mixtures were analyzed without further derivatization.  However, since the product 
molecules have masses that are below the detection limit of the MS (need m/z ≥ 100), the 
samples for the LC-MS analysis were derivatized with the fluorescent molecule fluram 
before dilution for the analysis.  This derivatization also gives better separation. 
Analytical techniques were also used to assay for FAD and H2O2.  In the Fms1 reaction 
FAD oxidizes the polyamines, forming reduced FADH2 in the process.  The reduced 
FADH2 are oxidized back to FAD by molecular O2 to form H2O2.  If we base the activity of 
our AofH on Fms1, the reaction shown in Figure 3.2 should occur and H2O2 should form 
as a side product. 
H2O2 can be detected in a number of ways by using coupled enzymatic assays.  One of 
these assays involves oxidation of H2O2 to H2O by the enzyme horseradish peroxidase.  
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This reaction can be coupled to various other redox reactions and can be observed by a 
change in colour, change in UV absorbance or fluorescence. 
FAD FADH2
O2H2O2
AofH
RHN NH2 H2N O
 
Figure 3.2:  The postulated oxidation of polyamines by AofH and FAD to form 3-
aminopropanal and FADH2.  FAD is regenerated by the oxidation of FADH2 by 
molecular O2 to H2O2. 
We used both photometric and fluorometric assays to determine whether H2O2 was being 
formed.  In the photometric assay 4-aminoantipyrine is oxidized during the reduction of 
H2O2.  This reagent condenses with vanillic acid to form a red quinoneimine dye, which 
can be monitored by an increase of absorbance at 498nm.  In the fluorometric assay non-
fluorescent homovanillic acid is oxidized during the reduction of H2O2 and condenses 
with itself to form a highly fluorescent 2,2’-dihydroxy-3,3’-dimethoxybiphenyl-5,5’-
diacetic acid.  The formation of the fluorescent compound can thus be measured directly. 
Apart from the direct analytical methods used to determine the products of the enzymatic 
reactions, we also used a genetic method in the form of functional complementation 
studies.  This involves the complementation of PanD activity (formation of β-alanine) in a 
∆panD strain with a plasmid that contains either FMS1 or aofH. 
We also assayed AofH for monoamine oxidase (MAO) activity.    Instead of a polyamine, 
the monoamine benzylamine was used as substrate for the AofH reactions.  In a MAO 
reaction this substrate would be oxidized to benzaldehyde and the formation of this 
product can be followed spectrophotometrically. 
Finally, photometric and fluorometric scans were also performed to determine the FAD 
content of the purified proteins. 
In this chapter these analytical techniques are discussed along with the results obtained 
from the AofH reactions. 
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3.2  Thin Layer Chromatography 
To identify the products of the AofH enzymatic reaction with the polyamines we used the 
method described by Sternglanz et al. (2) in their study of Fms1.  In this procedure the 
enzymatic reaction mixtures are derivatized with dansyl-chloride (Dns-Cl), a reagent that 
reacts with primary amines (See Figure 3.3).  This reagent is non-fluorescent when in its 
unbound state, but once it is bound it is highly fluorescent.  Aliquots (5µl) are spotted on 
silica plates and subsequently resolved with an eluant consisting of 3:1 cyclohexane:ethyl 
acetate.  The spots are visualized with UV light at 312nm. 
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Figure 3.3:  Derivatization of spermidine with Dns-Cl to form a fluorescent 
compound.  Dns-Cl is not fluorescent in its unbound form. 
The advantages of this method of analysis are that it is relatively quick, easy and cost 
effective which makes it ideal for initial analysis.  It is also easy to change the mobile 
phase and very little solvent is required.  The disadvantage is poor resolution, especially 
with samples of which the components have a great deal of structural similarity such as 
the polyamines.  We derivatized with Dns-Cl since this fluorescent method is more 
sensitive than staining with some of the commercial stains for primary amines, such as 
ninhydrin.  Based on the RF-values obtained we compared the reaction mixtures to stock 
samples of the substrates and postulated products.  However, this limits the identification 
power and makes the identification of side and unpredicted products difficult.  The 
results obtained here had to be confirmed with other analytical techniques such as HPLC 
and MS. 
To determine the RF-values of the substrates and expected products of the AofH and Fms1 
reactions, stock solutions of the four polyamines (spm, spd, N1-spm and N8-spd) and of 
the 3-carbon molecules (β-alanine, 3-aminopropanal, 3-aminopropanol and L-aspartate) 
were made.  These stocks were analyzed on TLC and the results are summarized in Figure 
3.4.  As can be seen on the figure, 3-aminopropanal, 1-amino-3,3-diethoxypropane and L-
aspartate all have high RF values and run up high on the plate.  Spm and spd have slightly 
lower RF-values.  The alcohol product is situated halfway between the spm/spd spots and 
the origin while N1-spm and N8-spd hardly moves from the origin.  According to 
Chapter 3: Activity of AofH 
 60
literature the spots for putrescine and 1,3-diaminopropane are situated between the top 
two spots on the plate (2).  The light spot represents the unreacted Dns-Cl that forms a 
yellow stain on the plate. 
As can be seen from Figure 3.4, it is nearly impossible to distinguish between the spots 
that have similar RF-values.  For example, spermine and spermidine or 3-aminopropanal 
and 1,3–diaminopropane are especially hard to distinguish.  This makes it difficult to 
determine whether, for example, the oxidation of spermine occurred and formed spd or 
not.  Despite this shortcoming, we decided to use this technique to get an initial indication 
of the reactivity of AofH. 
 
 
 
 
 
 
 
 
Figure 3.4:  Figurative representation of the position of the different compound spot 
when analyzed on TLC.  
We also determined the sensitivity of this technique by measuring the lowest product 
concentrations that can be visualized as Dns-Cl derivatives.  The minimum concentration 
of spm, spd and N1-spm that could be visualized was in the range of 25-100µM and for 
N8-spd and the 3-carbon products it was 50µM.   
The enzymatic reactions of the polyamines with Fms1 were resolved on TLC and used as 
a standard for the analysis of the AofH reactions (refer to Figure 3.5).  The results obtained 
from the resolved Fms1 enzymatic reactions confirmed that the oxidation of N1-spm 
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occurs by the appearance of the spd spot and the absence of the N1-spm spot (lane 9).  To 
a lesser degree a reaction with N8-spd could also be confirmed (lane 12).  No conclusion 
could be drawn from the reaction mixtures of spm (lane 3) while spd (lane 6) is not a 
substrate of Fms1.  The reactions with AofH did not compare well to the Fms1 standards.  
 
Figure 3.5:  Result of the TLC analysis of the AofH and Fms1 enzymatic reactions.  
Each set of three contains the substrate stock and the analysis of the enzymatic 
reactions of the substrate with AofH.  In some of the reactions a spot is present 
halfway between the origin and top spm/spd spots.  The RF value of this spot 
corresponds with that of 3-aminopropanol. The question mark indicates that this 
compound is not normally a product of polyamine oxidation.  This figure was 
manipulated with Adobe Photoshop to combine different pictures for easier 
comparison of the different enzymatic reactions, and to optimise contrast. 
As in the case of the reaction of Fms1 with spm and spd, it is difficult to determine if the 
postulated polyamine oxidation reactions occurred of AofH with spm (lane 2) and spd 
(lane 5).  As can be seen in lane 8, the spot for N1-spm (lane 8) is still present with no 
formation of a spd spot; the same can be said of N8-spd (lane 11).  Although the predicted 
spots were not present for the AofH reactions, there were spots half way between the 
origin and the top spm/spd spots for the reactions with spm (lane 2), spd (lane 5) and N1-
spm (lane 8).  This spot was also present for the Fms1 reaction with spd (lane 6).  Since 
these spots are present for all the different substrates, this had to be a fragment common 
to all the substrates.  If we look at the different structures in Figure 3.6 it is clear that they 
all have the spd backbone.  From the TLC analysis we know that this breakdown product 
is not spd, but has to be a smaller fragment.  The only logical fragment consists of 3 
carbon atoms and a primary amine group.  The only compounds satisfying this 
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requirement are β-alanine, 3-aminopropanal, 3-aminopropanol and 1.3-diaminopropane.  
We’ll refer to these compounds as the 3-carbon products.  The stock samples of the  
3-carbon products were analyzed on TLC (refer back to Figure 3.4).  The RF-value of the 
middle spot corresponded to that of 3-aminopropanol.  We set out to confirm this result 
with other analytical techniques. 
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Figure 3.6:  The 3-carbon fragment (in bold) that all the substrates have in common. 
3.3  Reverse phase HPLC 
The limitation with the TLC analysis was that the resolution was insufficient to 
distinguish between certain compounds.  HPLC is more versatile in this regard since the 
composition of the mobile phases can be changed during a run, thus making more 
complex separations possible.  Changes in the mobile phases can be gradual, as in the case 
of gradient elution, or sudden, as the case of step programs.  The flow rate can also be 
varied.   
Using such an analysis we hoped that the different substrates and 3-carbon products 
could be resolved and the different compounds of the enzymatic mixtures identified.  To 
increase the sensitivity of the method, the enzymatic reactions were derivatized with 
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fluorescent molecules for visualization.  We experimented with different fluorescent 
molecules that are discussed individually below.  Two of these molecules (Dns-Cl and 
NBD-Cl) were used for the analysis of all the amines (polyamines and 3-carbon products) 
while OPA/β-mercaptoethanol and fluram were only used to analyze the 3-carbon 
products. 
3.3.1   Analysis of all the amines 
3.3.1.1  Dansylated products 
The first fluorescent molecule used was Dansyl chloride (Dns-Cl).  All analyses made use 
of reverse phase C18 columns.  The program and mobile phases initially used were based 
on the published procedure in the Phenomenex HPLC catalogue (3).  This consisted of a 
step program of 35 minutes where mobile phase A was 65% ACN in ddH2O and B 93% 
MeOH in ddH2O.  No separation was obtained and the background was too high, 
possibly due to the formation of single and double substituted products.  Optimization of 
the derivatization protocol, to eliminate this problem, was not successful. 
The samples were also analyzed according to the procedure of Cervelli et al. (4). This is 
another step program over a period of 12min with the mobile phases ddH2O and 
acetonitrile (ACN) containing 0.5% trifluoroacetic acid (TFA), but no separation was 
obtained.    
3.3.1.2  NBD-Cl 
4-Chloro-7-nitrobenzofurazan (NBD-Cl) is a reagent that reacts with free amines to give a 
fluorescent substituted product.  The reaction scheme of the reagent with 3-aminopro-
panol is given in Figure 3.7.  We used this reagent to see whether chromatograms could be 
obtained with less background peaks since previous reports have indicated increase 
success of the analysis of amines with this reagent (5, 6). 
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Figure 3.7:  Derivatization of 3-aminopropanal with NBD-Cl. 
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Standards of the different polyamines and 3-carbon products were prepared and 
analyzed.  Initial experiments were carried out with the mobile phases ddH2O + 0.1% TFA 
and ACN + 0.1% TFA, but no separation was obtained. 
The second set of experiments were based on the method of Toyooka et al. (5) which used 
isocratic elution with the mobile phases 93% methanol (MeOH) and ACN + 0.1% TFA, but 
again no separation was obtained.  However gradient elution with ddH2O + 0.1% TFA 
and 100% MeOH gave distinctive retention times (tR) for the polyamines and 3-carbon 
standards.   (Refer to Table 3.1)  
Table 3.1:  Retention times of the NBD-Cl derivatives of the polyamines and the three carbon 
products 
Stock Retention time (min) 
Spermine 23,5 
Spermidine 22,5 / 24,5 
N1-acetyl spermine 24,5 
N8-acetyl spermidine 26,0 
β-alanine 32,0 
3-amino propanal Multiple peaks: 25,0 – 35,0 
3-amino propanol 32 
In the analysis of the enzymatic reactions the background problem reoccurred which 
made analysis of the chromatograms difficult.  Once again this problem was thought to be 
based on the formation of single and double derivatized products.  To circumvent this 
problem the enzymatic reactions were derivatized with an excess of the NBD-Cl so as to 
only form the doubly-derivatized compounds.  However, in subsequent analyses the high 
background problem persisted, indicating that derivatization efficiency was not the 
problem. 
3.3.2  Analysis of the 3-carbon products 
3.3.2.1  o-Phthaldialdehyde and β-mercaptoethanol 
o-Phthaldialdehyde (OPA) reacts with primary amines in the presence of the reducing 
agent β-mercaptoethanol in alkaline medium to form fluorescent compounds (7, 8) as 
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shown in Figure 3.8.  The analyses were based on the method used by Landry et al. (2).  
Gradient elution was used by changing from 100% Buffer A (100mM CH3COONa) to 
100% Buffer B (MeOH + 0.1% TFA) over a period of 30 min.    
 
Figure 3.8:  Derivatization of 3-aminopropanol with o-phthaldialdehyde. 
In the analysis of the 3-carbon stock solutions, separation of 3 minutes was obtained 
between the stocks of β-alanine (tR = 19.5min) and 3-aminopropanol (tR = 22.5min).  (Refer 
to Figure 3.9)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9:  Separation of OPA derivatives of β-alanine and 3-aminopropanol.  The 
resolution when one of the mobile phases is CH3COONa (top) is better than with ddH2O. 
H
H
O
O
N OHH2N OH+
O
O
Chapter 3: Activity of AofH 
 66
The solvent system, however, gave unreasonably high backpressures on the reverse phase 
C18 column we used.  This problem was subsequently addressed by using ddH2O as 
solvent instead of buffer.  This resulted in poor resolution.  Due to the problem with high 
backpressure, enzymatic reactions were never analyzed. 
3.3.2.2  Fluram 
Fluorescamine (fluram) reacts with primary amines to form fluorescent derivatives (refer 
to Figure 3.10), while the reagent itself and its hydrolysis product are not fluorescent.  
Derivatization at pH 9 occurs at room temperature with a half-life of a few seconds, while 
excess reagent is hydrolyzed just as quickly (9). 
 
 
 
Figure 3.10:  Derivatization of β-alanine with fluram 
Clear distinctions could be made between peaks corresponding to β-alanine, 3-
aminopropanal and 3-aminopropanol (refer to Figure 3.11), but not between the 
polyamines.  Unfortunately, all attempts to analyze the enzymatic reaction were 
unsuccessful as unreacted polyamine derivatives gave high background signals which 
made identification of the 3-carbon products impossible. 
3.3.3  Conclusion on HPLC 
Separation of the polyamines was achieved when derivatized with NBD-Cl.  The 
enzymatic reactions, however, gave too much background for conclusive analysis.  
Subsequently, we decided to focus on identifying the 3-carbon product of the reaction.  
Since efficient separation of the compounds derivatized with Dns-Cl or NBD-Cl was not 
obtained, we also tried OPA/β-mercaptoethanol and fluram.  Although the OPA method 
gave efficient separation, unreasonably high backpressures were obtained.  With fluram 
efficient separation was obtained for the 3-carbon products, but the background caused 
by the polyamine derivatives in the enzymatic reactions made analysis difficult.  We thus 
decided to analyze the enzymatic reactions with mass spectroscopy. 
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Figure 3.11:  Overlayed chromatograms indicating the separation of the 3-carbon 
products.  The products, β-alanine, 3-aminopropanal and 3-aminoproponol, were 
derivatized with o-phthaldialdehyde in β-mercaptoethanol and separated on a C18 
reverse phase column.  Elution was isocratic at 1ml.min-1 flow rate from 100% Buffer 
A (100mM CH3COONa) to 100% Buffer B (MeOH + 0.1% TFA) over a period of 30 
min. 
3.4  ESI-MS and LC-MS analysis 
ESI-MS analysis was used to determine products obtained in the enzymatic reactions.  
Due to the problems with background peaks and insufficient separation, the products 
obtained could not be confirmed with HPLC.   
The reaction mixtures of MBP-AofH and Fms1 with the four polyamine substrates were 
analyzed with ESI-MS in the ES+ mode.  Product peaks were only observed for the 
reaction of Fms1 with spermine (refer to Figure 3.12) and N1-acetylspermine (data not 
shown).  In the spectra shown, the spermidine peak at m/z = 146.1929 and spermine at 
m/z = 203.2 can be seen on the top spectrum of the Fms1 reaction.  The product fragment 
is absent in the mass spectrum of AofH. 
In both the ESI-MS and LC-MS the product peaks for the AofH reactions were absent, 
while the substrate peaks were prominent.  Comparing the ESI-MS spectra of the AofH 
reactions with those of the Fms1 standards indicate that these enzymes do not share the 
same function, or that AofH is inactive.  No product peaks were present on the LC-MS 
spectra, which indicate that both the enzymatic reactions did not occur.  However, 
derivatization with fluram was effective. 
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Figure 3.12:  ESI-MS spectra (ES+ mode) of the enzymatic reactions of Fms1 (top) and 
AofH (bottoms) with spermine.  The peak for the product spermidine is observed in 
the top spectrum at m/z = 146.1929 and for the substrate spermine at m/z = 203.2. 
Only the enzymatic reactions of spm with MBP-AofH and Fms1 were analyzed with  
LC-MS.  In this round of analysis the reaction mixtures were derivatized with fluram and 
analyzed in the ES− mode.  The results for the reaction were identical, as can be seen from 
the chromatograms in Figure 3.13.  Analysis of the data in the box showed that these 
peaks all correlate with each other.  Unfortunately we observed no product peaks on the 
mass spectra. 
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Figure 3.13:  ESI-MS analysis (ES− mode) of the enzymatic reaction of AofH and Fms1 
with spm.  In the top picture the top two chromatograms were recorded with the LC 
PDA detector and the bottom two with the MS detector.  The bottom picture is the 
typical mass spectrum that was obtained for all substrate containing peaks.  The peak 
at m/z = 378.2 is doubly charged spermine-fluram, m/z = 757.4 is singly charged 
spermine-fluram and at m/z = 295.1 = hydrolyzed fluram. 
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Analysis of the spectra obtained with this technique was complicated by the formation of 
singly and doubly charged molecules.  As can be seen in the mass spectrum, the only 
peaks that could be identified were the singly-charged (m/z = 757.4) and doubly-charged 
(m/z = 378.2) spermine-fluram derivative bands and the hydrolyzed fluram peaks (m/z = 
295.1).   
3.5  Functional complementation studies 
Since direct analyses of the enzymatic reactions were inconclusive, we set out to use a 
genetic method to determine the activity of AofH.  One of these methods is functional 
complementation of activity.  In functional complementation a deletion strain, lacking a 
certain metabolic function, is used. In our case the strain lacked the ability to 
biosynthesize β-alanine via the decarboxylation of L-aspartate.  To restore the wild-type 
phenotype, a plasmid containing a gene sequence whose gene product has a similar 
function (the oxidation of the polyamines to form β-alanine precursors, for example) is 
transformed into the deletion strain.  In short, the handicap in the function of the deletion 
strain is complemented by the plasmid-encoded gene (10).  The study is initiated by 
growing the desired colonies in or on minimal media.  We thus set out to test whether 
AofH will complement ∆panD strains by the formation of the β-alanine precursor 3-
aminopropanal from spermine. 
3.5.1  In E. coli 
3.5.1.1  Plate assays 
Four ∆panD strains were identified for complementation studies.  They are E. coli DV1, E. 
coli DV62, E. coli DV79 and JW0127.  These strains cannot synthesize β-alanine de novo.   
E. coli DV1 is a mutant that cannot grow on pantothenate and requires β-alanine for 
growth even on rich medium (11).  E. coli DV62 is a temperature sensitive mutant (12) 
while E. coli DV79 has a pantothenate kinase enzyme that is only 29% as active as the wild 
type enzyme (13).  JW0127 is a ∆panD that was created in the laboratory of Prof Hirotada 
Mori as part of a concerted effort to replace every gene in the E. coli genome with the gene 
encoding kanamycin resistance (14).  The plasmid used for complementation was the 
Gateway™ pBAD-DEST49 with the araBAD promoter which is induced with L-arabinose 
(which can be added to the minimal media).  We decided to use the araBAD promoter 
since it provides tight, dose-dependent regulation of heterologous gene expression based 
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on the concentration of L-arabinose in the media.  The T7 promoters of the pDEST- and 
pET- vectors allow a degree of leaky expression.  The cloning of this plasmid is described 
in chapter 2, section 2.2.6.  A pETBlue-based plasmid with its tetracycline-promoter was 
also considered as a possibility, but cloning of the genes into these plasmids failed.   
For the functional complementation experiments minimal medium plates were used that 
were supplemented with either β-alanine, L-aspartate, pantothenate or spermine and the 
appropriate antibiotics.  The predicted results are summarized in Table 3.2.  pBAD-
EXP49-panD was the positive control that should grow on all the LB plates.  pBAD-EXP49-
gus served as the negative control and was created from the test plasmid (pGus) that is 
supplied in all the Invitrogen Gateway™ LR clonase kits.  pBAD-EXP49-aofH should 
theoretically grow on the plates supplemented with β-alanine, pantothenate and spermine 
and not on the plates supplemented with L-aspartate or on minimal media alone.  The 
predicted results are given in Table 3.2. 
Table 3.2:  Predicted result for complementation in the ∆panD -strains.  √ indicates expected 
growth and × no growth.   
Substrate added pBAD-EXP49-gus pBAD-EXP49-panD pBAD-EXP49-aofH 
Control × √ × 
β-alanine √ √ √ 
Pantothenate  √ √ √ 
L-aspartate × √ × 
Spermine × √ ? 
Inconclusive set of results were obtained for the functional complementation of AofH in 
E. coli DV1, E. coli DV62 and E. coli DV79.  As expected, the strains without plasmid grew 
only on LB plates; however, the strains with plasmid showed no growth discrimination 
with the different additives.  In the experiment shown in Figure 3.14 for the functional 
complementation experiment in E. coli DV79, the strains containing pBAD-EXP49-panD 
and pBAD-EXP49-aofH grew on minimal media (E-salts and glycerol) as well as media 
containing 0.01% spermine.  Both plasmid-containing strains were expected to grow on 
the minimal media plates containing 0.01% spermine, but only pBAD-EXP49-panD is 
expected to grow on just minimal media.  No growth was observed for the cultures that 
contained the negative control plasmid, pBAD-EXP49-gus. While the expected results 
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were obtained in the case of the negative control experiments, the problem is that both the 
panD and aofH containing strains grew on both plates.  In the case of the panD containing 
strain this is not a problem, since L-aspartate is not an essential metabolite and can be 
sourced from elsewhere.  Spermine however is not essential and it is also reported to be 
absent in E. coli.  This indicates that the deletion strains are able to source β-alanine via an 
unknown route, one of which may be the oxidation of spermidine to 3-aminopropanal.  
This reaction, however, has not been verified to date. 
 
Figure 3.14:  Functional complementation in E. coli DV 79.  Growth was expected for 
only the pBAD-EXP49-panD contaning culture on the minimal media plate and forf 
pBAD-EXP49-panD and pBAD-EXP49-aofH on the 0.01% enriched spermine minimal 
media plates.  The fact that growth occurred of both plasmid containing strains on 
both plates indicates that these plasmid containing cultures are able to source β-
alanine via an unknown route. 
The study with JW0127 was also inconclusive.  Growth was obtained in all media with all 
supplements.  The only difference was that the strains that contained pBAD-EXP49-gus 
and pBAD-EXP49-aofH grew more vigorously on β-alanine and pantothenate 
supplemented plates than the strain that contained pBAD-EXP49-panD.  This result was 
not expected and could not be explained to date. 
3.5.1.2  In Solution 
Minimal media supplemented with the metabolites described above were inoculated with 
the JW0127 strain transformed with the different plasmids mentioned above, and 
subsequently grown at 37˚C.  The increase in optical density was measured at 600nm over 
a period of 48 hours.  The results obtained are displayed in Figure 3.15.  The growth rate  
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Figure 3.15:  Functional complementation of the different plasmids in liquid media 
from the cell strain JW0127. 
for all three plasmids in β-alanine (blue lines) and pantothenate (brown lines) was 
basically identical, as was expected.  With spermine (yellow lines) all three strains have a 
lag period of 24 hours before growth starts.  This lag might be explained due to the 
Chapter 3: Activity of AofH 
 74
absence of spermine in wild-type E. coli.  These strains are also affected by a biomass exess 
after 40h.  With L-aspartate (pink line) another interesting result was obtained.  Only the 
panD containing strain was not affected by a biomass exess after 24h.  The influence that 
adversely affected the growth of the strains in spermine and L-aspartate enriched media 
could not be indentified, although there were suggestions that this may be pH related.  
Moreover, no difference was observed in the growth rates between the cultures 
containing the negative control strain, pBAD-EXP49-gus and pBAD-EXP49-aofH.  This 
indicates that the expression of AofH does not alleviate the lack of PanD more than any 
other protein.  These results also suggest that the decarboxylation of L-aspartate by PanD 
is not the only source of β-alanine in E. coli.   
3.5.2  In S. cerevisiae 
Since the complementation in E. coli gave inconclusive results, we set out to attempt 
complementation in the baker’s yeast S. cerevisiae.  The idea was to base the 
complementation on the work of Liu et al. in which ∆FMS1 strains were complemented 
(15).  The ∆FMS1 strain, BY4742 was a gift from the Institute of Wine Biotechnology 
(IWBT) at Stellenbosch.  pYES-EXP52-aofH was successfully constructed, but not the 
positive control plasmid pYES-EXP52-FMS1.  Although the experiments seemed viable, 
transformation of the plasmids into the cell line failed. 
3.5.3  Conclusion on complementation 
The survival of the ∆panD deletion strains, even in the case of the negative controls (in 
solution), indicates that the organism can obtain β-alanine via another route than the 
decarboxylation of L-aspartate.  This is surprising since it has been accepted that no other 
source for β-alanine exists in E. coli.  No conclusive complementation results were 
observed.  Based on the fact that similar growth rates, although not end bio-masses, were 
obtained with the negative control and pBAD-EXP49-aofH in the complementation studies 
using the JW0127 strain, genetic methods in E. coli were not successful to determine the 
activity of AofH. 
3.6  Test for monoamine oxidase activity 
When we first identified AofH as an Fms1 homolog, the enzyme was described on 
Tuberculist as a “putative polyamine oxidase (PAO)” (16).  Somewhere during the course of 
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the study the description of AofH on the website changed to a “putative monoamine oxidase 
(MAO)”.  To test if this was indeed the case, a relatively easy spectroscopic assay was 
used as described by Tabor et al. (17).  This assay is based on the difference of the 
extinction coefficients between benzylamine (substrate of MAO) and benzaldehyde (the 
product of the monoamine reaction).  Benzaldehyde absorbs at 250nm and benzylamine 
does not.  The reaction of benzylamine with MBP-AofH was monitored at 250nm, but no 
increase in absorption was observed in any of the sets.  This led to the conclusion that no 
benzaldehyde formed and that the cloned AofH does not display MAO activity.   
3.7  Assay for the presence of H2O2 
The results obtained from the TLC analyses of the AofH enzymatic reactions suggested 
that 3-aminopropanol might be formed as a product of the reaction.  This is an unusual 
result for the PAO’s, since the first step of polyamine oxidation leads to formation of an 
aldehyde (refer back to Figure 3.2).  To form an alcohol from the aldehyde requires a 
reduction step as shown in Figure 3.16.   
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 Figure 3.16:  Proposed reaction for the formation of 2-aminopropanol from 3-
aminopropanal via a PAO reaction. 
Before this unusual activity could be investigated further, the dependence of AofH on the 
cofactor had to be confirmed. Furthermore, we had to identify whether the normal 
product of FADH2 oxidation to FAD was formed or not.  To test whether FADH2 is 
oxidized back to FAD by O2 via the known route, or if the oxidizing agent is indeed the 
aldehyde, we assayed for H2O2. 
3.7.1  Horseradish peroxidase assay 
The first assay used to determine the formation of H2O2 was a continuous 
spectrophotometric assay as described by Palcic et al. (18) for MAO reactions.  This same 
method was used by McIntire et al. to determine the steady-state kinetics of murine PAO 
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(19).  In this assay horseradish peroxidase (HRP) reduces H2O2 to water while  
4-aminoantipyrine is oxidized.  (Refer to Figure 3.17)  This reagent condenses with vanillic 
acid to form a red quinoneimine dye, which has an extinction coefficient of 4654cm-1 at pH 
7.6.  It has also been shown that the absorbance at 498nm increases proportionally to the 
amount of H2O2 reduced (19).   
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Figure 3.17:  H2O2 assay.  Horseradish peroxidase reduces H2O2 to H2O while at the 
same time oxidizing 4-aminoantipyrine.  The oxidized product binds with vanillic 
acid to form a quinoneime dye that has a distinctive red color. 
All analyses were done in triplicate and included reactions of both enzymes (Fms1 and 
MBP-AofH) with 5 different substrates (spm, spd, N1-spm, N8-spd and benzylamine).  
Benzylamine is a monoamine oxidase (MAO) substrate and was used in all assays to test 
for MAO activity (refer back to section 3.6).  Only the reactions of Fms1 with N1-spm 
yielded a positive result.  This means that Fms1 showed no activity with compounds that 
are known substrates of the enzyme, indicating that this method was not sensitive 
enough.  The analyses were also time-consuming with an average analysis taking 30min. 
To test if the low sensitivity of this method was due to the assay itself or due to the 
sample preparation, two minor changes were done in further investigations.  The first of 
these involved the addition of FAD to all reaction mixtures to a final concentration of 
0.05mM (20).  Due to the problems experienced during purification, the protein may have 
Chapter 3: Activity of AofH 
 77
denatured.  To overcome these effects, a second assay was done that made use of the 
enzymatic crude extract.  No activity was found with either of these experiments.   
3.7.2  Fluorescent assay 
Landry et al. reported activity of Fms1 with spm, N1-spm and N8-spd and have 
determined the steady-states kinetics of the enzyme with these substrates (2).  The HRP 
assay used so far showed that only spm is a substrate of Fms1.  Due to the low sensitivity 
of the previous assay, we decided to repeat the experiment with a fluorescent assay (2). 
In this coupled assay described by Guilbault et al. non-fluorescent homovanillic acid is 
oxidized by H2O2 to highly fluorescent 2,2’-dihydroxy-3,3’-dimethoxybiphenyl-5,5’-
diascetic acid.  (Refer to Figure 3.18)  The initial rate of the formation of the fluorescent 
compound can be related back to the activity of the target enzyme.   The formation of the 
fluorescent compound is measured at λex=315nm and λem=425nm (21). 
 
Figure 3.18:  Fluorescent assay for H2O2 with horseradish peroxidase and 
homovanillic acid. 
The assays were done in triplicate and included enzymatic reactions of Fms1 and Nus-
AofH with the same 5 substrates as before.  (Refer to Figure 3.19)  The reactions of Fms1 
with spm (pink lines), N1-spm (turquoise lines) and N8-spd (purple lines) formed 
fluorescent compounds as expected.  However, the reaction with N8-spd was slower than 
the reactions with spm and N1-spm.  Spermidine (yellow line) and benzylamine (brown 
line) are not substrates of Fms1.  None of the Nus-AofH reactions yielded positive results.  
The Nus-AofH reactions were also supplemented with 0.05mM FAD, but no difference in 
results was observed.   
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Figure 3.19:  Graphs of the fluorescent assays of the Fms1 and Nus-AofH reactions.  
The graph at top is of the reactions of Fms1 with the different substrates and the graph 
at the bottom is of AofH with the different substrates.  
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3.8  FAD Scans 
From the H2O2 assays it can be concluded that AofH either does not use O2 to oxidize 
FADH2 back to FAD, or that the enzyme is inactive.  So far we have tested for the 
formation of H2O2, but have not confirmed the presence of FAD.  To accomplish this 
fluorescent scans of the three purified enzymes were recorded.  The extinction coefficient 
of FAD = 11.3mM.cm-1 and the scans taken with the λex = 370nm and scanned over λem = 
420 – 680nm.   
The graphs obtained from the scans (Figure 3.20, top graph) of Fms1 (turquoise line), Nus-
AofH (purple line) and MBP-AofH (brown line) were compared to those recorded for 
three FAD standards of different concentrations of 20µM (blue line), 10µM (pink line) and 
1µM (yellow line).  Emission peaks were observed for the standards and Fms1, but not for 
Nus-AofH or MBP-AofH.  
Photometric scans were also performed from 300nm to 700nm using these same samples.  
The signature two peak absorbance of FAD was present in the scans of the 20µM and the 
10µM standards and of Fms1, but not in the scans of Nus-AofH, MBP-AofH and the 1µM 
standard.  However, the background absorbance of the two AofH-fusions was higher than 
the absorbance of the 1µM FAD standard.  Furthermore, the concentrations of Nus-AofH 
(0.22mg.ml-1) and of MBP-AofH (0.25mg.ml-1) were much lower than that of Fms1 
(0.86mg.ml-1).  To overcome this problem both AofH fusions were spun down to pellet 
any debris or denatured protein that may be present in the samples.  The supernatant was 
subsequently concentrated.   To determine whether the AofH samples were concentrated 
enough, the following calculations were done: 
Mr (Fms1) = 58.833kDa    
Mr (MBP-AofH) = 94.410kDa   
Mr (Nus-AofH) = 105.889kDa 
[Fms1] = 0.861g.l-1 / 58.833kDa = 0.0146mM = 14.6µM 
[MBP-AofH] = 0.790g.l-1 / 91.140kDa = 0.0086mM = 8.6µM 
[Nus-AofH] = 0.152g.l-1 / 105.889kDa = 0.0012mM = 1.2µM 
FAD binds in a molar ratio of 1:1 to Fms1.  For our calculation we made the assumption 
that AofH binds to FAD in the same molar ratio.   
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Figure 3.20:  FAD scans.  The top graph is the fluorescent scans and the bottom graph 
the photometric scan.  In the photometric scan the background absorbance of MBP-
AofH is very high and it may appear that the enzyme indeed contains flavin.  Further 
experiments, however, indicated that this was not the case. 
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Since we found that FAD concentrations of 10µM could easily be visualized, the FAD in 
MBP-AofH should also be visible.  However, in the case of Nus-AofH the concentration of 
protein was obviously too low to be detected.  The scans with these proteins were 
repeated and although the background absorbance was reduced, no FAD peaks could be 
observed.  This lead to the conclusion that none of our AofH fusions were purified bound 
to FAD.   
As discussed in section 2.5, denatured His-AofH was also refolded in the presence of 
FAD.  To test whether the refolding was successful, the refolded enzyme was also 
scanned for FAD content.  No FAD was detected in these scans and we concluded that the 
refolding of AofH was unsuccessful or that it does not bind FAD. 
3.9  Conclusion 
Different analytical methods were used to determine the products of the AofH enzymatic 
reactions with the various polyamine substrates.  The first set of analyses was performed 
on TLC.  From these we concluded that AofH forms 3-aminopropanol as a product from 
all the polyamines.  This would be a most surprising result, since no other flavin-
containing enzyme is known to catalyze a similar reaction.  Unfortunately none of the 
experiments done further could confirm this result; in fact, AofH seemed to be inactive in 
every additional analysis performed.  We finally set out to confirm the presence of the 
FAD cofactor in the enzyme by variety of methods.  These lead us to conclude that the 
AofH fusions did not contain FAD, and that the observed spots on the TLC analyses of 
the AofH-catalyzed reactions could not be due to 3-aminopropanol, or that is was formed 
by some non-enzymatic process. 
Further efforts to refold the protein in the presence of FAD had also failed, as detailed in 
Chapter 2, making it impossible confirm the activity of AofH by biochemical methods. 
However, our attempts at confirming the enzyme’s activity by genetic methods also 
proved inconclusive.  From the functional complementation studies we were only able to 
conclude that the ∆panD mutants (grown in solution) were in fact able to source β-alanine 
from other metabolic pathways, making it impossible to determine whether cell lines 
containing aofH could indeed produce a β-alanine precursor at low levels.  Taken 
together, our study shows that the confirmation of the presumed activity of AofH will 
remain elusive until the enzyme can be purified in its active form, i.e. with FAD bound. 
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3.10  Experimental 
3.10.1   Cloning, overexpression and purification of Fms1 
Plasmid pJWL94 that comprises of the plasmids pET28a (+)-FMS1 and Codon+ RIL, was a 
gift from Rolf Sternglanz of State University of New York Stony Brook, USA.  The enzyme 
was expressed from BL21 (DE3) at a 500ml scale in LB media containing 40mg.l-1 
kanamycin and 50mg.l-1 chloramphenicol.  The expression was induced at OD600 = 0.64 
with a final concentration of 0.45mM IPTG, 3% ethanol and incubated with vigorous 
shaking at 18°C overnight.  The cells were harvested by centrifugation at 4 500rpm for 
30min at 4°C, resuspended in a volume 10× the pellet weight in His-tag binding buffer 
and lysed with sonication.  Fms1 was purified with affinity chromatography on a 1ml 
Sigma HIS-Select™ cartridge using the ÄKTAprime-system with His-tag binding buffer 
(20mM Tris-HCl, 5mM imidazole, 500mM NaCl, pH7.9) and His-tag elution buffer (20mM 
Tris-HCl, 500mM imidazole, 500mM NaCl, pH7.9).  After elution all protein samples were 
desalted (also on the ÄKTAprime-system) using an Amersham Biosciences 5ml HiTrap™ 
desalting column and gel filtration buffer (25mM Tris-HCl, 5mM MgCl2, 5% glycerol,  
pH 8.0).  The protein concentration was determined with the Bradford reagent and BSA 
standards as 0.86mg.ml-1. 
3.10.2   TLC 
The experimental procedures were based on the article by Sternglanz et al. (2).  All 
enzymatic reactions were carried out in 10mM potassium phosphate buffer, pH 7.2, 
200mM NaCl, 0.4mM polyamine and containing ±1.25µg enzyme in a total volume of 
50µl.  The reactions were incubated at 37°C for 1hour after which they were boiled at 95°C 
for 5min to denature the enzyme.  Polyamines were derivatized by adding 3× the reaction 
volume of dansylchloride (Dns-Cl) (10mg.ml-1 in acetone) to the reaction mixture.  The 
reaction mixture was saturated with Na2CO3 and incubated at 50°C for 30min.  5µl was 
spotted on 0.2mm thick silica covered plastic TLC plates form Merck.  The mixtures were 
resolved with the eluant 2:3 cyclohexane:ethyl acetate mixture and the spots visualized 
with UV light at 312nm.   
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3.10.3   Synthesis of standards 
3-aminopropanal was synthesized from 1-amino-3,3-diethoxypropane by hydrolysis of 
the ethoxy-groups.  1.3mmol 1-amino-3,3-diethoxypropane was stirred in 20ml 0.1M HCl 
at room temperature for 45 min.  Aliquots were derivatized with Dns-Cl and resolved on 
TLC to assess the reaction.  The solvent was removed under reduced pressure and the 
resulting colorless oil washed with ddH2O until HCl the odour was absent.  The liquid 
was diluted with ddH2O and lyophilized overnight.  The resulting product was stocked 
and stored at -20°C.  
3.10.4   HPLC 
For HPLC analysis a Phenomenex 5µ Luna C18(2) reverse phase column (unless specified 
otherwise), size 250 × 4.6mm was used with the Waters Alliance 2960 Separation module.  
All compounds were visualized with a Waters 474 Scanning fluorescent detector.  All 
solvents were HPLC grade (Riedel-de Haën®) and purchased from Sigma-Aldrich.  The 
buffers were filtered through 0.45micron membrane and degassed by sonication. 
3.10.4.1  Dansylated products 
Mobile phase A was 65% ACN in ddH2O and B 93% MeOH in ddH2O.  A gradient 
program from 100%A to 100%B in 28 minutes, a hold step for 2 minutes at 100% B and a 
gradient back to 100% A over 5 minutes was used at a flow tempo of 1ml.min-1 (3).  
Chromatography was recorded at excitation 337nm, emission 530nm, gain 10 and 
attenuance 256. 
For the analysis according to the procedure of Cervelli et al. (4) a 5µm Gemini C18 110Å 
reverse phase column, dimensions 250 × 4.6mm, was used.  Mobile phase A = 0.5% TFA in 
ddH2O and B = 0.5% TFA in ACN.  The chromatography was performed at flow rate of 
0.1ml.min-1 and a gradient of 0 to 45% B from 0 to 0.1min, 45-80%B from 0.1 to 8min, hold 
at 80%B from 8 to 11min, 80-90% B from 11 to 12 min.  The compounds in 10µl of sample 
were detected at λex = 337nm, λem = 530nm, gain = 10 and attenuance = 256.  
3.10.4.2  NBD-Cl 
Stock solutions were prepared by mixing 100µl 20mM polyamine, 100µl 0.1M NaHCO3 
and 400µl 0.5% NBD-Cl in ethanol together and incubating the reaction mixtures for 
60min at 55˚C in the dark (22).  The chromatography was visualized at λex = 337nm and 
λem=530nm.  For the first sets of experiments the mobile phases A = 0.1% TFA in ddH2O 
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and B = 0.1% TFA in ACN were used and a number of gradient programs were 
investigated.   The second set of experiments used isocratic elution with 70% A and 30% B 
where mobile phase A was 93% methanol in ddH2O and mobile phase B was 0.1% TFA in 
ACN.   
To obtain the chromatographic parameter of the various standard compounds the 
following program was used:  100% A to 50% A over 30min; back to 100% A from 30 to 
35min and hold at 100% A until 40 min at flow rate 1ml.min-1 and the oven temperature at 
25˚C.  The detector was set at λex=430nm, λem=550nm, gain 10 and attenuance 256 for 
analysis of 10µl of stock solutions. 
The enzymatic reaction mixtures were prepared as described in section 3.10.2 and the 
derivatization with NBD-Cl as described earlier.  For the derivatization with larger 
excesses of NBD-Cl 100µl enzymatic reaction (0.4mM polyamine) was added to 98µl 0.1 M 
NaHCO3 and 2µl 0.25M NBD-Cl (2.5mM) and incubated at 50˚C for 60min.  5µl of the 
samples were injected onto the column. 
3.10.4.3  o-Phthaldialdehyde and β-mercaptoethanol 
Samples were derivatized by using 100µl enzymatic mixture/stock solution with 90µl 
0.05M Borate buffer, pH 9.5, 1.5µl 10mg.ml-1 OPA in EtOH and 1.5µl 5µl.ml-1  
β-mercaptoethanol in EtOH.  After incubation of 1 minute at room temperature, 5µl of the 
samples were injected onto the column.  Elution was isocratic at 1ml.min-1 flow rate from 
100% Buffer A (100mM CH3COONa) to 100% Buffer B (MeOH + 0.1% TFA) in 30 min at 
25˚C.  Fluorescent detector was set at λex=340nm, λem=455nm, attenuance 256 and gain 10.   
3.10.4.4  Fluram 
For analysis a 5µm Gemini C18 110Å reverse phase column, 250 × 4.6mm, was used.  To 
obtain separation, an isocratic program was used with 20mM CH3COONa, pH 5.9 and 
30% ACN at 1ml.min-1 flow rate and 25˚C.  Fluorescence during chromatography was 
detected at λex=390nm, λem=475nm, gain 10 and attenuance 256.  Enzymatic reactions were 
done as described in section 3.10.2.  After the incubation time elapsed, the 50µl reactions 
were boiled at 95°C for 5min and 2.5µl NaOH (2M) added.  The protein was precipitated 
with centrifugation and 50µl supernatant used further.  To the supernatant was added 
145µl 500mM borate buffer, pH10 and 50µl 0.3mg.ml-1 fluram in ACN (23).  Samples of 
10µl were injected onto the column. 
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To separate the polyamines, different ratios of ACN and CH3COONH4; pH 6.0 was tried 
without success. 
3.10.5   ESI-MS and LC-MS analysis 
The ESI-MS analysis was done by Dr Andre Venter of the mass spectroscopy unit at the 
central analytical facility of Stellenbosch University on a Waters API Q-TOF Ultima.  For 
the analysis the following parameters were used:  capillary voltage = 3.5kV, cone  
voltage = 35, RFI = 40, source = 120ºC, desolvation temperature = 350ºC, desolvation gas = 
400l.h-1, cone gas = 50l.h-1 and the source was ESI+. 
Dr Marietjie Stander did the LC-MS analysis on the same instrument as above at the 
central analytical facility of Stellenbosch University.  The sample were introduced with a 
Waters Alliance 2690 on a 5µm Gemini C18 110Å reverse phase column, 250 × 4.6mm, by 
isocratic elution with mobile phase 30%ACN 70% 10mM CH3COONH4 at a flow rate 
1ml.min-1 with and a 4:2 split to the MS.   As for the MS analysis the following parameters 
were used:  capillary voltage = 3.5kV, cone voltage = 35, RFI = 40, source = 100ºC, 
desolvation temperature = 350ºC, desolvation gas = 400l.h-1, cone gas = 50l.h-1 and the 
source was ESI−.  
3.10.6   Functional complementation studies 
3.10.6.1  In E. coli DV-strains 
Overnight cultures were made of the colonies containing the constructs pYES-EXP49-aofH, 
pYES-EXP49-panD and pYES-EXP49-gus.  These overnight cultures were streaked on 
minimal media plates (E-salts, 0.2% glycerol, 0.001% thiamine, 0.01% methionine, 
100mg.ml-1 ampicillin, 0.2% L-arabinose and 0.2% agar).  The metabolites (β-alanine,  
L-aspartate, pantothenate and spermine) were added to a final concentration of 0.01%.  
Complementation was also tried from minimal media (same composition as above, just 
without agar). 
3.10.6.2  In JW0127 
Complementation was only carried out with the plasmid pYES-EXP49-aofH, pYES-EXP49-
panD and pYES-EXP49-gus.  All the plate and liquid assays used minimal media, as 
described above, with added 30mg.ml-1 kanamycin.  All liquid assays were on 1ml scale. 
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3.10.7   Test for monoamine oxidase activity 
96-well Corning flat bottom UV-STAR microtiter plates were used for the analysis on the 
Thermo Varioskan™.  Three sets of reactions were done, each in triplicate.  The first set 
contained no enzyme, the second set Fms1 and the third set MBP-AofH.  The reaction 
mixtures consisted of 200µM potassium phosphate buffer, pH 7.2, 10µM benzylamine, 
and 15µg of enzyme.  The reaction was started with the addition of enzyme and the 
increase of absorption monitored at 250nm and 37°C. 
3.10.8   Assays for FAD activity 
3.10.8.1  HRP 
The reaction mixtures consisted of 0.2M potassium phosphate buffer, pH 7.2, 1mM 
vanillic acid, 0.5mM 4-aminoantipyrine, 4U.ml-1 of HRP, 0.8µg PAO enzyme and 0.5mM 
substrate.  The reactions were initiated with the addition of the PAO enzyme and the 
increase in absorbance monitored at 498nm for at least 30min at 25°C.  All analyses were 
done in triplicate on 300µl scale in Corning 96 well microtiter plates on a Thermo 
Varioskan™ and Skanit software version 2.2.1. 
3.10.8.2  Fluorescent assay 
For the fluorescent based assay, 300µl of enzymatic reaction mixture was analyzed in 
black Nunc non-treated 96-well F-bottom multiwell plates from AEC Amersham.  The 
reactions mixtures contained 50mM Tris-HCl pH 9.0, 18U HRP, 1mM homovanillic acid, 
0.5mM substrate and 2.34µg enzyme.  The reactions were initiated with the addition of the 
substrate.  All analysis was performed on a Thermo Varioskan™ and Skanit software 
version 2.2.1.  Readings were taken at λex = 315nm and λem = 425nm every 1s for 60s for the 
Fms1 reactions.  For the AofH reactions measurements were taken over the same time 
span, but with larger intervals between each measurement. 
3.10.8.3  FAD scans 
The Thermo Varioskan™ at 25˚C was used for all the scans.  Black Corning 96-well 
microtiter plates were used for the fluorescent scans.  λex = 370nm and scanned over the 
range of λem = 420 – 680nm with a 5nm step size and excitation bandwidth of 12nm.   
Corning UV Star 96-well microtiter plates were used for the photometric scans.  The 
samples were scanned from 300nm to 700nm.   
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C h a p t e r  4  
L-Aspartate-α-Decarboxylase: 
Overview and development of possible inhibitors 
4.1  Introduction 
L-Aspartate-α-decarboxylase (PanD) decarboxylates L-aspartate to form β-alanine and 
CO2.  As was mentioned in chapter 1 this enzyme forms part of the small class of 
pyruvoyl-dependent enzymes that includes the histidine, arginine, S-adenosylmethionine 
(SAM) and phosphatidylserine decarboxylases, and proline reductase.  Due to our failure 
to show the formation of β-alanine precursors from the oxidation of the polyamines, we 
shifted our focus to PanD since we expected that this enzyme, and not AofH, may be the 
main source of β-alanine production in Mtb. 
The L-aspartate-α-decarboxylases from different organisms share a high degree of 
sequence conservancy as can be seen in Figure 4.1.  Among the strictly conserved residues 
are Lys9, His11, Thr16, Tyr22, Gly24, Ser25, Asp29, Asn51, Arg54, Thr57, Tyr58, Gly72, Ala73, Ala74, 
Asp82, Ile85 and Asn111 (numbering based on the sequence of PanD purified from H. pylori) 
(1).  Twelve of these residues are located around the active site although they are not all 
on the same chain.  The Lys9, His11 and Arg54 residues that form part of the active site are 
located on an adjacent chain of the homotetramer (1, 2). 
The crystal structure of E. coli PanD was solved at 2.2Å resolution (3).  This structure 
consists of a homotetramer with pseudo four-fold rotational symmetry (refer to Figure 4.2, 
structure b).  Each strain comprises of a 6-stranded β-barrel capped by small α-helices at 
both ends.  (Refer to Figure 4.2, structure a)  Of the four chains in the tetramer only three 
contain the active pyruvoyl site.  The fourth has the ester intermediate functionality (3, 4).   
The crystal structure for H. pylori PanD has also been solved at 2.0Å resolution for the apo 
structure and 1.55Å for the iso-asparagine bound complex.  Iso-asparagine is a structural 
analogue of L-aspartate and was used to study the binding interactions in the active site 
(Figure 4.2, boxed) (1). 
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Figure 4.1:  Sequence alignment of PanD’s from different species constructed on T-
coffee (5).  The highly conserved residues mentioned in the text are indicated with 
arrows. 
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Figure 4.2:  The crystal structure (top 2 pictures) and schematic representation of the 
active site (in block at bottom) of H. pylori PanD.  Picture (a) represents the monomer 
(in ribbon presentation) with the pyruvoyl group covalently bound to iso-asparagine 
(ball and stick presentation).  Picture (b) is the protein tetramer. The dashed lines in 
the active site representation indicate the distances between the active site residues 
and the bound isoasparagine groups in Å.  (Figure reprinted with permission of 
Elsevier from the article of Byung II Lee and Se Won Suh. (2001) Crystal Structure of the 
Schiff Base Intermediate Prior to Decarboxylation in the Catalytic Cycle of Aspartate-α-
Decarboxylase. Journal of Molecular Biology 340 (1), 1-7 © 2001 (1).) 
The most important covalent interaction in the active site is the formation of the iminium 
ion (Schiff base).  As far as the non-covalent interactions are concerned, a salt bridge 
forms between Arg54 and the β-carboxylate of L-aspartate.  This leads to the selectivity 
toward β-amino acids.  Other interactions include hydrophobic packing interactions with 
Trp47 and hydrophilic with Thr57.  These interactions may be the reason why α- and β-
branched compounds don’t bind, but β-hydroxy compounds do.  Lys9 and His11 stabilized 
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the α-carboxylate functionality on the opposite side of Arg54.  The selectivity of these 
residues seems to be weaker, since a degree of chain extension is possible for the 
substrates in this area (6). 
Based on our knowledge of sequence homology between the different PanD’s and on the 
active site, we set out to design an inhibitor for Mtb PanD. 
4.2   Inhibitors 
There are two approaches for the rational design of inhibitors for PanD.  The first is to 
inhibit the self-processing cleavage that leads to the formation of the pyruvoyl group.  The 
second is to develop a substrate-based inhibitor that would inhibit the decarboxylation 
reaction (1). 
4.2.1  Inhibition of pyruvoyl formation 
Mtb PanD is translated into an inactive pro-enzyme called the π-protein.  The activation of 
the enzyme is temperature dependent and occurs with the formation of the pyruvoyl 
groups.  The residues Gly24 and Ser25 are involved in this modification.  As is shown in 
Figure 4.3 the process starts of with nucleophilic attack of the hydroxyl oxygen of Ser25 on 
the carbonyl group in Gly24 (4.1).   This N-O acyl shift via an oxazolidine intermediate 
leads to the formation on an ester intermediate (4.3).  The alpha proton in relation to the 
Ser carbonyl group is abstracted and the resulting charge stabilized through resonance.   
β-elimination of the ester containing chain leads to the formation of the PanD β-chain of 
2.74kDa (4.4).  The longer α-chain (4.5) of 13.22kDa now ends with dehydroalanine.  
Rearrangement to the imine and subsequent hydrolysis forms a carbonyl group.  This 
gives rise to the two adjacent carbonyl groups of the pyruvoyl group (4.6) (2, 7). 
The cleavage of the PanD to form the pyruvoyl groups was found to be temperature 
dependent.  Optimum cleavage occurs at 37˚C (physiological temperature) and the rate of 
cleavage decreases with increase of temperature.  Complete cleavage of the Mtb enzyme is 
obtained after 24hours.  This corresponds to the doubling time of the mycobacterium (7). 
As far as the inhibition of the formation of the pyruvoyl group is concerned, studies have 
been done to mutate the residues involved in protein maturation in vitro (8).  However, 
these effects have not been studied in vivo and furthermore no small molecule has yet 
been identified that can prevent the post translational process from happening.  As a 
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result, we decided to focus on the design of a small molecule that is a structural analogue 
of L-aspartate and can act as a mechanism-based inhibitor. 
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Figure 4.3:  Formation of the pyruvoyl group 
4.2.2  Structural- and mechanism- based inhibitors  
A mechanism-based inhibitor is an inactive compound that has structural similarity to the 
substrate or product of the target enzyme.  These compounds are converted by the action 
of the target enzymes to intermediates that are reactive and can normally deactivate the 
same enzyme.  One of the problems with creating a mechanism-based inhibitor for PanD 
is that this enzyme has a similar reaction mechanism to the enzymes that use the cofactor 
pyridoxal 5’-phosphate (PLP).  Even so, this would not normally be a problem since 
enzymes are very specific for their substrates and the inhibition of one group of enzymes 
would not necessarily affect the function of another group.  In this case, however, the PLP 
dependent aspartate aminotransferase also binds aspartate.  Some of the other reactions 
that the PLP-dependent enzymes catalyse include racemization, transamination, retro-
aldol cleavage, decarboxylation (9) and α,β- and β,γ-eliminations (10) and further 
examples of these enzymes include arginine decarboxylase, cysteine synthetase, serine 
hydroxymethyltransferase, alanine racemase and 3,4-dihydroxyphenylalanine (11).  
Various ways to inhibit the PLP-dependent enzymes have already been described and 
include inhibition by structural analogues (9, 12), and metal ions (10).  The transaminase 
enzymes are also inhibited by aminooxyacetate, semicarbazide, cyanide and isoniazid 
(13).   
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As in the case of the pyruvoyl group, the PLP cofactor reacts with the amine functionality 
on the target molecule to form a Schiff base (refer to Figure 4.4) where it acts as an 
electron sink for the charge generated during the enzymatic reaction.  In mechanism-
based inhibition the PLP enzymes convert the inhibitor into an electrophile.  However, for 
the inhibition of the pyruvoyl group we focused on the design of an inhibitor that would 
convert the pyruvoyl group into a nucleophile, which would then attack a nearby 
electrophile to form a covalent bond.  This method of deactivation would distinguish our 
PanD inhibitor from other PLP inhibitors, offering some selectivity.    
N
H
OH-2O3PO
O
O-
-O
O
O
NH2
N
H
OH-2O3PO
NH+
O-
-O
O
O
H2O
H2O
 
Figure 4.4: Binding of the PLP cofactor to the substrate.  The formation of the Schiff 
base is a mechanistic characteristic that these enzymes share with the pyruvoyl group 
of enzymes (compare to Figure 1.4) 
In our studies we focused on the design of a mechanistic inhibitor that is a structural 
analogue of the natural substrate of PanD, L-aspartate.  To do this however the inhibitors 
that have already been identified for PanD first have to been reviewed. 
4.3  Overview of inhibitors for E. coli PanD 
Shive and Mascow already identified the first inhibitor of PanD in 1946, although at that 
time it was not recognized as such.  This, however, led to the discovery of the function of 
L-aspartate in pantothenate biosynthesis.  Their experiments with β-hydroxyaspartate 
caused inhibition of cellular growth in test cultures.  This inhibition was lifted by addition 
of asparagines, pantothenate and aspartate.  Inhibition also occurred when the cultures 
were treated with cysteic acid, a structural analogue of aspartate (2).  Soon thereafter  
E. coli PanD was purified to near homogeneity, and it was confirmed that the 
decarboxylase is inhibited by D-serine, β-hydroxy-D,L-aspartate and L-cysteic acid (14). 
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Webb et al. (6) performed a binding screen with E. coli PanD in which they tested 55 
compounds that bear the primary amine functionality.  The covalent adducts that formed 
were identified with MALDI-TOF spectroscopy after the enzyme was incubated with the 
possible substrates in the presence of NaCNBH3.  From these analyses they reached the 
following conclusions about which structures will not bind in the active site (L-aspartate is 
used as reference for discussions): 
1. Extension in the linker between the α-carbon and β-carboxylate is unfavourable.  
Example of molecule:  L-glutamate. 
2.  Extension in the chain between the α-carbon and the α-amino group is unfavourable.  
Example of molecule:  2-aminomethylsuccinate. 
3. Increase in chain length between the α-carbon and α-carboxylate is tolerated, for 
example β-glutamate.  These compounds cannot act as substrates, but they are 
promising competitive inhibitors. 
4. Both α- and β-branching are unfavourable except in the case of β-hydroxyaspartate 
and D-serine.  Example of molecules for which binding is unfavourable:  α- and β-
methyl aspartate. 
Although these experiments were not done with Mtb PanD, the active site is presumed to 
have a great deal of similarity to the active site of the E. coli enzyme, (refer to Figure 4.1).  
We could therefore use these principles in the design of an inhibitor. 
4.4  Design of an inhibitor 
In the design on an inhibitor we focused on compounds that are substrate analogues of  
L-aspartate, since they are the most likely to bind to the enzyme.  We decided to 
synthesize an inhibitor by adding a potential good leaving group in the β-position of  
L-aspartate.  This would act as an efficient way of deactivating the enzyme.   Based on the 
work done on E. coli inhibitors substitution in the β-position of L-aspartate with a methyl 
group is unfavourable.  However, β-hydroxyaspartate and D-serine do bind to the 
enzyme.  Webb et al. (6) postulated that this discrepancy in their analysis might be due to 
hydrophilic interactions in the active site with Thr57 (refer to active site, Figure 4.2 box).  
The inhibitors investigated and considered for this study are shown in Figure 4.5.  Even 
though β-hydroxyaspartate (4.7) binds to the enzyme, it is a known competitive inhibitor 
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of PanD (2).  We set out to synthesize β-fluoroaspartate (4.8) and test it as a possible 
inhibitor.  The F-atom is small, so steric interference in an active centre designed to fit an 
H-atom would be kept to a minimum.  Fluorine is also a good leaving group and due to 
its high electronegativity, the hydrophilic interaction in the active site should not prevent 
binding as in the case of the methyl substituents. 
 
Figure 4.5:  Possible inhibitors of PanD.  β-hydroxyaspartate (4.7) is a known inhibitor 
and we investigated fluorine-substituted analogs, β-fluoroaspartate (4.8) and α-
fluoromethylaspartate (4.9). 
Another possible inhibitor we wanted to investigate was α-fluoromethylaspartate (4.9).  
However, α-branching is unfavourable according to Webb’s analysis. Moreover,  
α-fluoromethylaspartate is unstable and prone to cyclization.  The postulated deactivation 
mechanism of β-fluoroaspartate with PanD is given in Figure 4.6. 
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Figure 4.6:  Proposed mechanism of action of a mechanism based inhibitor of PanD.  
The structural analogue of L-aspartate contains a leaving group that is eliminated 
during the enzymatic process to form a terminal double bond.  This can attack the 
glyoxylate carbonyl group to form a covalent bond. 
As shown in the figure, the decarboxylation of the substrate analogue still occurs (step B).  
The first difference is in the step where the substrate would have picked up an H+.  
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Instead of this happening, the leaving group would rather be eliminated (step C).  In the 
following step abstraction of the H+ on the methyl group of the pyruvoyl group would 
lead to the substrate protonation (step D).  This complex can be hydrolyzed from the 
pyruvoyl group to form glyoxylate instead of β-alanine (step E).  The terminal double 
bond that formed from what used to be the pyruvoyl group can now act as a nucleophile 
and attack the aldehyde functionality of the glyoxylate (step F) and a covalent bond 
forms. 
4.4.1 Synthesis of an inhibitor 
4.4.1.1  Overview 
The synthesis scheme of β-fluoroaspartate (4.8) is shown in Figure 4.7.  We based the 
synthesis of β-fluoroaspartate on the synthesis of β-hydroxyaspartate.  Although  
β-hydroxyaspartate is commercially available, it is expensive with 250mg costing R2 
437.38 (Sigma-Aldrich).   
 
Figure 4.7:  Proposed synthesis of β-fluoroaspartate 
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We decided to pursue the synthesis of this precursor based on the published procedure of 
Ozaki et al. (15).  This method consists of the condensation of methylisocyanoacetate (4.11) 
and glyoxilic acid (4.12) to form an oxazoline ring (4.13).  The ring is hydrolyzed by 
aqueous HCl to form β-hydroxyaspartate (4.7).  The product is purified with ion exchange 
chromatography by using an acidic Amberlite® IR-120(plus) column, eluting the product 
with 5% NH4OH solution and recrystallization from H2O.  To obtain β-fluoroaspartate, 
protected β-hydroxyaspartate is required.  In the postulated synthesis the carboxylic acid 
groups would be protected by formation of the methyl esters and the amine functionality 
with di-t-butyl dicarbonate (BOC group).  The β-hydroxy-group could then be exchanged 
by reaction with diethylamino sulphurtrifluoride (DAST) and deprotected to give β-
fluoroaspartate.    
4.4.1.2  Attempts at the synthesis 
α-Isocyanoacetamide (4.11) was synthesized by stirring methylisocyanoacetate (4.10) in a 
solution of NH3 in MeOH (16).  The formation of 4.11, a black sticky substance, was 
confirmed by 1H-NMR.  (DMSO-d6), 4.3ppm (2 × H’s).   β-Hydroxyaspartate (4.7) was 
prepared via intermediate 4.13 according to the procedure of Ozaki et al. as described 
above.  Purification was attempted with the correct equivalent of Amberlite (1g binds 
4.4meq) and repeated four times.  Efficient binding and purification did not occur.  
Since the purification of β-hydroxyaspartate was troublesome, we decided to isolate and 
purify the oxazoline ring (4.13) before attempting hydrolysis, in a second synthesis.  The 
purification of 4.13 was attempted by recrystallization from MeOH.  This proved to be 
unsuccessful and the efforts to isolate 4.13 were abandoned and the oxazoline ring was 
hydrolyzed with aqueous HCl and lyophilized.  The solvent was removed in vacuo and 
the powder refluxed in a solution of anhydrous HCl in MeOH to form crude 4.14 (17).  To 
synthesize 4.15, crude 4.14 derivatized with di-tert-butyl dicarbonate.  The product was 
extracted from the reaction mixture with CHCl3, dried and the solvent remove in vacuo.  
However, the product extracted was a brown sticky substance that could not be resolved 
with TLC. 
The synthesis was repeated to form the oxazoline ring (4.13) for a third time in which we 
attempted to synthesize the protected β-hydroxyaspartate methyl ester (4.14) directly by 
refluxing 4.13 with dry HCl in MeOH overnight.  The solvent was removed in vacuo and 
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the product purified on a silica column and the fractions sobtained analyzed with 1H-
NMR.  According to these spectra, none of the samples contained the product. 
4.4.1.3  Conclusion on synthesis 
The synthesis of β-fluoroaspartate was more difficult than anticipated.  The biggest 
problem is the failure to purify β-hydroxyaspartate (4.7) from the reaction mixture.  To 
side step this purification step direct protection of 4.7 was investigated by refluxing with 
dry HCl and derivatization of the primary amine with a BOC-group.   Unfortunately the 
less polar product that formed did not prove easier to purify.  An additional problem that 
hampered progress on the synthesis of the inhibitor is the low yield of the hydrolysis 
steps, which afforded very little product in our hands.  This combination of factors led to 
a third unsuccessful attempt to synthesize the inhibitor.  Instead, we decided to focus our 
attention on the development of qualitative and quantitative assays to test for possible 
inhibitors. 
4.5  Testing of substrates and inhibitors 
4.5.1  Overview of existing assay methods 
The existing assay methods for PanD were all designed to determine the steady-state 
kinetics of the enzyme.  Assays to determine the steady-state kinetics of Mtb PanD activity 
was done by Chopra et al. (7) and for E. coli PanD by Ramjee et al. (4) and Williamson et al. 
(14).  Chopra (7) and Ramjee (4) both used stop assays based on the derivatization of L-
aspartate and β-alanine with fluorescamine (fluram).  Aliquots of the enzymatic reaction 
were taken at given time intervals, the enzymatic reaction quenched, derivatized with 
fluram and the components separated and quantified with HPLC (7).  Williamson and 
Brown (14) assayed PanD activity by measuring the release of 14 CO2.  They trapped the 
gas with hyamine and measured the radioactivity with a scintillation counter.  Another 
method used was to measure the formation of [14C]-β-alanine from either [U-14C]-
aspartate or [4-14C]-aspartate with separation by chromatography and subsequent 
scintillation counting (14). 
We set out to develop assay methods that did not involve radioactive compounds.  Firstly 
we wanted a qualitative method to test whether certain compounds are substrates of 
PanD or not.  For this reverse phase HPLC was used.  Secondly a quantitative method is 
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required to compare different substrates and inhibitors with each other.  To fulfil this 
requirement a coupled enzymatic assay was used. 
4.5.2  Testing with HPLC 
With the HPLC method we wanted to identify whether or not certain compounds are 
substrates of PanD.  To accomplish this, enzymatic reactions were analysed of Mtb PanD 
with different substrates.  After derivatization with fluram these compounds were 
analyzed with HPLC on a C18 column.  The obtained results were analysed by 
comparison to the retention times of stock solutions of the presumed substrate/inhibitor 
and the postulated products to determine whether the enzymatic reactions occurred or 
not.  The inhibitors investigated are shown in Figure 4.8 along with the postulated 
products. 
  
 
 
 
 
 
Figure 4.8:  The inhibitors investigated and the theoretical products that would form it 
they were decarboxylated.  
In our initial HPLC analysis reaction mixtures were derivatized with OPA and β-
mercaptoethanol.  Although analysis could be done in this manner, we found that the 
aspartate derivative was not very stable under these derivatization conditions.  Literature 
confirmed that the diacidic amino acids aspartate and glutamate are unstable and 
therefore show loss in fluorescence when derivatized with OPA (19).  Furthermore our 
studies of the AofH reaction with fluram (section 3.3.2.2) proved successful, both 
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pertaining to the stability of the derivatized compounds and reproducibility of the 
analysis.  As a result, we decided to continue the studies with the fluram derivatives. 
With the HPLC analysis we expected to see product peaks in the chromatogram of the 
enzymatic reaction with L-aspartate, but not for the enzymatic reactions with α-methyl-
D,L-aspartate (4.17) and β-hydroxyaspartate (4.7).  The chromatograms of the PanD with 
L-aspartate (1.6) clearly showed the formation of β-alanine (1.2) (Figure 4.9, top).  No 
product peak were present for the reaction of PanD with α-methyl-D,L-aspartate (4.17) 
(Figure 4.9, bottom) as was expected, since is it known that this compound does not bind 
to PanD (6).  Interestingly, the chromatograms of β-hydroxyaspartate (4.7) showed the 
formation of isoserine (4.19) (Figure 4.9, middle).   From these results we conclude that  
L-aspartate and β-hydroxyaspartate are substrates of PanD, while α-methylaspartate is 
not.  To compare the effectiveness of the decarboxylation reaction of the two substrates, 
the steady-state kinetics have to be determined. 
4.5.3  Developing assays for steady-state kinetics 
In the reaction of PanD with L-aspartate, the two products, CO2 and β-alanine, could both 
be assayed (refer to Figure 4.10). 
CO2 can be assayed by labelling with 14C and measuring the release of radioactive CO2 
(14).  A coupled enzymatic assay of CO2, based on the enzymes phosphoenolpyruvate 
carboxylase (PEPC) and malate dehydrogenase has also been described.  This assay 
coupled the production of CO2 to the decrease of NADH in the assay mixture. 
Unfortunately L-aspartate is an allosteric inhibitor of PEPC, and thus this assay cannot be 
used to assay PanD (2). 
The second product, β-alanine, has previously been assayed by derivatization with fluram 
and quantification on the HPLC (4, 7) as well as by radioactive labelling with 14C (14).  
Alternatively, the production of β-alanine can be measured by a coupled enzymatic 
reaction based on the activity of the β-alanine-utilizing enzyme PanC.  However, such an 
assay requires an optimized assay of PanC. 
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Figure 4.9:  Chromatograms from HPLC analysis of the substrates, their postulated 
products and the enzymatic of the substrates with PanD as fluram derivatives.  All 
analyses were done on a C18 column with and isocratically eluted with 20mM 
CH3COONa and 30% ACN at 1ml.min-1 flow rate.  The substrate peaks are all green, 
the product peaks blue and the analysis of the reactions are shown in black.  In the 
bottom graph the chromatograms of the α-methyl-D,L-aspartate stock and of the 
reaction are identical, therefore only one spectrum is observed.   
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Figure 4.10:  The enzymatic reaction of PanD with L-aspartate to form β-alanine and 
CO2. 
4.5.3.1  Assays for PanC activity 
E. coli PanC was used in all the assays.  As can be seen in Figure 4.11, PanC catalyses the 
condensation of β-alanine and pantoic acid in the presence of ATP.  The three products 
that form, namely AMP, pantothenic acid and pyrophosphate (PPi), can be used to assay 
for PanC activity. 
 
Figure 4.11:  The enzymatic reaction of PanC with R-pantoic acid and β-alanine to 
form pantothenic acid.  In this reaction ATP is used and AMP and PPi formed. 
4.5.3.2  Assay with AMP 
The first assay (Figure 4.12, A) we investigated makes use of a coupled enzymatic reaction 
where the AMP produced from the PanC reaction is converted to ADP by the enzyme 
adenylate kinase (Adk, also known as myokinase) in the presence of ATP.  This ADP is 
used by pyruvate kinase (PK) to reduce phosphoenolpyruvate (PEP, 4.21) to pyruvate 
(4.22).  ATP is regenerated and is recycled back into the Adk reaction.  The pyruvate (4.22) 
is further reduced to lactate (4.23) by lactate dehydrogenase (LDH) in the presence of 
NADH.  For every molecule of pantothenate (1.1) formed in the PanC reaction, one 
molecule of NADH is oxidized to NAD+.  The kinetic parameters can thus be determined 
by measuring the decrease in NADH at 340nm (17).  Kinetic analysis of the PanC reaction 
with this method was time consuming with an average run time of 30 minutes.  High 
concentrations of enzyme (± 150µg per 300µl reaction) were also required.  We therefore 
explored other possibilities for the coupled assays. 
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4.5.3.3  Assay using pantothenic acid 
The second method we tried was an assay that utilized pantothenic acid. (Figure 4.12, B)  
The PanC reaction was coupled with the reaction of pantothenate kinase (CoaA).  CoaA 
phosphorylates pantothenic acid (1.1) with the consumption of ATP to form ADP.  This 
ADP molecule is recycled into the PK and LDH reactions as described above.  This 
method was not an improvement on the previous assay as far as duration of the assay and 
amount of enzyme required was concerned. 
 Figure 4.12:  Coupled assay to determine the kinetic parameters of PanC.  All the 
assays measured the decrease of NADH at 340nm.  
4.5.3.4  Assay using pyrophosphate 
The third approach was to assay the PPi that formed.  This was done by using a Sigma® 
Enzymatic Determination of Pyrophosphate kit that contains a complete enzymatic 
method to assay the production of PPi with a coupled assay to NADH.  In the 
condensation reaction of β-alanine (1.2) and pantoic acid (1.3) in the presence of PanC and 
ATP, one molecule each of AMP and PPi are released per molecule of pantothenate 
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formed.  In the assay fructose-6-phosphate kinase catalyses the reaction of PPi with D-
fructose-6-phosphate to form D-fructose-1,6-diphosphate.  This molecule is degraded by 
the enzyme aldolase to from D-glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone 
phosphate (DHAP).  GAP is also converted to DHAP by triosephosphate isomerase.  
DHAP are reduced to glycerol-3-phosphate by glycerophosphate dehydrogenase in the 
presence of NADH (20).  For every one molecule of PPi consumed, two molecules of 
NADH are oxidized to NAD+.  The decrease of NADH is followed at 340nm. 
The kinetic parameters for PanC with β-alanine using this assay was determined as  
Vmax = 0.04 ± 0.002nmoles.s-1, KM = 121 ± 26µM, kcat = 0.018s-1 ± 0.001 and kcat/KM = 0.15 ± 
0.039.  The Michaelis-Menten curve fit is given in Figure 4.13 (top) and the literature 
values for the different PanCs and the assays used to determine them are given in  
Table 4.1.  Our kinetics parameters correspond well with the values obtained in literature. 
Table 4.1:  Steady state kinetic parameters for PanC with β-alanine according to literature and the 
assays used (2). 
Organism KM  (µM) kcat. (s-1)   kcat/KM Assay 
Mycobacterium 
tuberculosis 800 ± 0.1  4.3 × 10
3 
Coupled enzymatic 
assay (21) with Adk, PK 
and LDH 
Escherichia coli 950   
Coupled enzymatic 
assay (2) with Adk, PK 
and LDH 
Escherichia coli 56   14C labeled β-alanine (2) 
Escherichia coli 62.6   14C labeled β-alanine (2) 
Escherichia coli 530± 70   Microbiological assay (2) 
Escherichia coli 121 ± 26 0.018 ± 0.001 0.15 ± 0.039 Our assay with PPi kit 
4.5.3.5  Steady-state kinetics for PanD 
The kinetic parameters for the Mtb PanD reaction with L-aspartate were determined by 
using the coupled enzymatic reactions of PanC and PanD and assaying with the PPi kit.   
Two sets of reactions were done to test the influence of the amount of PanC on the 
enzymatic reactions.  In the first set ±5µg Mtb PanD and ±150µg PanC (all enzymatic 
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concentrations were determined with the Bradford reagent) was used per 300µl reaction 
and in the second set 5µg Mtb PanD and 137µg PanC.  
Figure 4.13:  The steady state kinetics of PanC with β-alanine (top) and PanD with 
varied L-aspartate (bottom).  Each point represents the average of three readings and 
the bars the standard error. Solid lines represent the best-fit of the data to the 
Michaelis-Menten equation. 
Only slight differences were noticed between these two sets of results.  The kinetic 
parameters for Mtb PanD were determined as Vmax = 1.3 ±0.7pmoles.s-1, KM = 210 ± 32µM, 
kcat = 0.0013 ± 0.00007s-1 and kcat/KM = 0.0061 ± 0.002.  The Michaelis-Menten curve fit is 
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given in Figure 4.13 (bottom) and the literature values and assay methods from which 
they were obtained are given in Table 4.2.  These results validated our coupled enzymatic 
method as the kinetic parameters we obtained for PanD compare well to the literature 
values. 
Table 4.2:  Steady state kinetic parameters for PanD according to literature and the assays used (2). 
Organism KM  (µM) kcat. (s-1)   Specific activity Assay 
Mycobacterium 
tuberculosis 
219.6 0.65 2 100 nmol/min/mg HPLC quantification of 
fluram derivatives(7) 
Escherichia coli 160 0.66  Formation of 14C labeled 
products(14) 
Escherichia coli 151 ± 16 0.57  HPLC quantification of 
fluram derivatives(4) 
Mycobacterium 
tuberculosis 
210 ± 32 0.002  Our coupled enzymatic assay 
(section 4.5.3.2) 
4.6  Conclusion 
We focused on the design of an inhibitor that is specific for the pyruvoyl-dependent PanD 
enzyme, as well as developing methods to assay such potential inhibitors.  The synthesis 
of β-fluoroaspartate as a PanD inhibitor was more cumbersome than anticipated and must 
be revisited.  Both qualitative and quantitative analytical techniques were designed to 
compare the reactions of PanD with substrate analogues of L-aspartate to each other.  
Reverse phase HPLC was employed to determine whether certain compounds are 
substrates of PanD, while a coupled enzymatic assay was developed to determine the 
steady-state kinetics.  Various assay methods were investigated to find an easy, quick and 
efficient enzyme coupled reaction for the steady-state kinetics and to study the inhibitory 
effects of different compounds on PanD.  Our assay of choice relied on the enzyme PanC, 
which uses the β-alanine produced by PanD to form pantothenate.  One of the side 
products of this reaction is pyrophosphate.  We assayed for PPi by using an assay kit that 
contains a complete enzymatic mixture to assay for the production of PPi by coupling its 
production to the utilization of NADH.  Our analysis of different compounds showed that 
as expected α-methyl-D,L-aspartate is not a substrate of PanD, but that β-
hydroxyaspartate is.  While the inhibitory effects of these molecules on PanD in the 
presence of L-aspartate have not yet been studied, this interesting result suggests that 
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substrates similar to β-hydroxyaspartate may be good mechanism-based inhibitors of 
PanD.  It also lends support to our hypothesis that β-fluoroaspartate is a possible 
mechanism-based inhibitor of PanD. 
4.7  Experimental 
4.7.1  DNA amplification, cloning, expression and purification 
The panD-gene sequence was amplified from genomic DNA from Mtb strain H37Rv with 
the forward primer 5’-ACATTGGAGAAACATATGTTACGGACGATGC-3’ and reverse 
primer 5’-TCGCCAGCAGCACTCGAGTCCCACACCGAG-3’.  The forward primer 
introduced an NdeI-site and the reverse primer an XhoI-site, both underlined in the 
primer sequences.  The stop codon was also removed.  Amplification was done in AMP-
buffer, 0.4mM dNTP mix, 1mM forward primer, 1mM reverse primer, 2ng genomic DNA, 
1.25U pfu and ddH2O to the final volume of 25µl with varied MgSO4 concentrations.  The 
PCR program had an initial step of 3 min at 94˚C followed by 30s at 94˚C, 30s at 55˚C and 
1min at 72˚C for 30 cycles.  This was followed by incubation at 72˚C for 10min and finally 
a hold step 4˚C.  Analysis of the reaction mixtures was done by electrophoresis on a  
1% agarose gel and the bands visualized by staining with SYBR® gold and viewed on a 
Darkreader.  Product bands at 420bp were obtained at 2.5, 3 and 3.5µM MgSO4. and were 
purified from the gel.   
The panD PCR product was digested with NdeI and XhoI and purified as described in 
section 2.7.2.  Ligation of 60 fmoles of digested panD with the same amount of digested 
pENTR4NT was done according to method 1 described in section 2.7.3.1 and transformed 
into DH5α.  The construct was confirmed with screening on 1% agarose gel in comparison 
to undigested pENTR4NT and by digestion with NdeI and XhoI to regenerate the insert.  
The regenerated insert was purified from the gel with the GFX PCR DNA and gel band 
purification kit and was used to ligate into digested pET28a(+).  31 fmoles of each was 
ligated using method 1 again.  To check that the correct construct formed screening on a 
1% agarose gel in comparison to undigested pET28a(+) and digestion check with NdeI 
and XhoI were done.  The plasmid was also sequenced.  pET28a-panD was transformed 
into BL21(DE3) and expressed from 500ml LB containing 30mg.l-1 kanamycin.  The 
inoculated media was incubated at 37°C, 200rpm shaking till OD600=0.6 was reached after 
which it was induced with a final concentration of 0.5mM IPTG at 30˚C overnight.  Cells 
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were harvested by centrifugation at 4500rpm for 30min at 4°C.  The pellet was 
resuspended in a volume of 10× the pellet weight of binding buffer and cooled down to 
below 10°C.  Lyses of the cells occurred by sonication and the cell debris was collected by 
centrifugation at 15 000rpm for 30min at 4°C and the supernatant filtered with an 
0.45micron filter and purified with affinity chromatography on a 1ml HiTrap Chelating 
HP columns the ÄKTAprime-system.  After desalting the concentration was determined 
with the Bradford reagent and BSA standards as 1.29mg.ml-1.  Purity of the enzyme was 
confirmed by running a 15% SDS PAGE gel. 
4.7.2  Synthesis of β-fluoroaspartate (4.11) 
All chemicals were purchased from Sigma-Aldrich and were of highest purity. 
Methylisocyanoacetate (4.15) (547.6mg, 5.53mmol) was stirred in 7.5ml NH3-solution (2M 
in MeOH) for 24 hours.  The solvent was removed in vacuo to yield an orange precipitate.  
This was dissolved in another portion of NH3-solution, stirred for another 24hours and 
the solvent removed again to yield a lighter orange precipitate.  The formation of α-
isocyanoacetamide was confirmed with 1H-NMR (DMSO-d6), 4.3ppm (2 × H’s).  
4.7.2.1  Synthesis of oxazoline ring (4.13) 
α-Isocyanoacetamide (4.16) (≈ 5,5mmol) was dissolved as is in 2.5ml MeOH and glyoxilic 
acid monohydrate (4.17)(556mg, 5.5mmol) added to it.  This mixture was added slowly to 
a stirring solution of NaOH (220mg, 5,5mmol) in 1.25ml ddH2O over a 30min period at 
temperature ≤ 15˚C (H2O bath with ice).  After everything was added the mixture was 
stirred for a further 30 min at 15˚C followed by 4.75h at room temperature.  The solvent 
was removed in vacuo and black sticky substance formed.  This was dissolved in ddH2O 
and lyophilized overnight to yield the sodium salt as a greenish powder. 
4.7.2.2  Ring opening with aqueous HCl 
For ring opening with aqueous HCl acid 3ml 3M HCl were added to the powder and 
refluxed for 2h at 70-80˚C.  The solvent was removed in vacuo with the rotary evaporator 
and lyophilized overnight.  A reddish brown substance was obtained.  Formation of  
β-hydroxyaspartate was confirmed on TLC (eluant: 50% butanol, 30% ddH2O and 20% 
CH3COOH; stain: 1.5% ninhydrin) in comparison with a commercial sample of  
β-hydroxyaspartate.  To purify 4.9 an acidic Amberlite column was used with the elution 
buffer 5% NH4OH, pH 11.0.   
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4.7.2.3  Ring opening with dry HCl 
For ring opening with dry HCl the sodium salt (800mg, 5mmol) was dissolved 5ml 
MeOH.  The slurry was added to a mixture of 20ml MeOH and CH3COCl (500µl, 7mmol) 
and refluxed for overnight (17).  The solvent was removed in vacuo to give a yellow 
brownish powder.  Purification was done on a silica column with the eluant 5% MeOH, 
1% triethylamine in CH2Cl2. 
4.7.2.4  Protection with BOC-group to form 4.15. 
For protection with the BOC-group, 2.2mmol of the 4.14 was dissolved in 2.4ml CHCl3.  
To this mixture was added (in this sequence) NaHCO3 (328mg, 3.9mol), NaCl (777mg, 
13.4mmol) and di-tert-butyl dicarbonate (851mg, 3.9mmol).  The reaction mixture was 
refluxed for 90min, extracted 4х 25ml CHCl3 and the product dried overnight on Na2SO4.  
The drying agent was filtered off and the solvent removed in vacuo (18). 
4.7.3  HPLC 
All analyses were done on a Waters Alliance 2960 system with 5µm Gemini C18 110Å 
reverse phase column, dimensions 250 × 4.6mm.  All solvents were HPLC grade (Riedel-
de Haën®) and purchased from Sigma-Aldrich.  The buffers were filtered through 
0.45micron membrane and degassed by sonication.  Fluorescence was detected with a 
Water 474 scanning fluorescent detector at λex=390nm, λem=475nm, gain 10 and attenuance 
256.  Enzymatic reactions were done in 50mM potassium phosphate buffer, pH 7.0, 1mM 
EDTA with 4mM substrate and incubated at 37˚C for 1h.  After the incubation time 
elapsed, the 50µl reactions were boiled at 95°C for 5min and 2.5µl 2M NaOH added.  The 
protein was removed by centrifugation and 50µl of the supernatant used in further 
applications.  To the supernatant was added 145µl 500mM borate buffer, pH10 and 50µl 
0.3mg.ml-1 fluram in ACN and left at room temperature for a minute to derivatize (7).  
Samples of 10µl were injected and isocratically eluted with 20mM CH3COONa and 30% 
ACN at 1ml.min-1 flow rate.   
4.7.4  Steady-state kinetics 
All reactions were done in triplicate on 300µl scale in Corning flat bottom microtiter 
plates.  The decrease of NADH was measured at 340nm over a period of 30 minutes using 
a Thermo Varioskan™ UV-spectrometer with Skanit software version 2.2.1. 
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4.7.4.1 Preparation of D-pantoic acid (1.3) 
To pantolactone (1mmol) was added 1M NaOH (1.1mmol) and ddH2O to give a final 
concentration of 100mM.  The solution was boiled at 95˚C for 1h. 
4.7.4.2  Coupled assay with myokinase, pyruvate kinase and lactose dehydrogenase 
The assay mixture consisted of 50mM Tris.HCl, pH 7.6, 10mM MgCl2, 20mM KCl, 5mM β-
alanine, 5mM D-pantoic acid, 10mM ATP, 2.5mM NADH, 10mM PEP, 7.5U PK, 7.5U 
LDH, 9U Adk and ddH2O.  Reactions were initiated with the addition of 65µg PanC.  The 
decrease of NADH was followed at 340nm for 30min. 
The reactions were repeated according to the protocol used by Zheng et al. (21) with assay 
mixture composition of 100mM Hepes, pH 7.8, 10mM MgCl2, 10mM ATP, 5mM β-alanine, 
5mM D-pantoic acid, 1mM PEP, 0.2mM NADH, 5.4U PK, 5.4U LDH, 5.4U Adk and 
ddH2O.  The reaction was done in the same way as above. 
4.7.4.3  Assay coupled to CoaA 
The assay mixture contained 100mM Hepes, pH 7.8, 10mM MgCl2, 1mM PEP, 5mM β-
alanine, 5mM D-pantoic acid, 5.4U PK, 5.4U LDH, 3µg CoaA and ddH2O.  The reaction 
mixture was incubated at 25˚C for 5min before the reaction was initiated with the addition 
of 65µg PanC.   The decrease of NADH was followed at 340nm for 30min. 
4.7.4.4  Assay with the Sigma Pyrophosphate kit. 
For an assay reaction 120µl of reagent supplied in the kit is used per 300µl assay reaction.  
The assay mixture contained 10mM Hepes, pH 7.8, 10mM MgCl2, 10mM ATP, 5mM  
β-alanine, 5mM D-pantoic acid, PPi reagent and ddH2O.  The master mix was incubated at 
25˚C before initiation of the enzymatic reaction with the addition of PanC.  The decrease 
of NADH was followed at 340nm for 5min. 
For the determination of the kinetic parameters of PanC in relation to β-alanine, 65µg 
PanC was used per 300µl reaction.  PanC was added to the master mix and the reactions 
were initiated with the addition of β-alanine.  Concentrations of β-alanine were varied as 
follows: 0, 0.01, 0.025, 0.05, 0.10, 0.15, 0.25, 0.50, 1.00 and 2.00mM. 
4.7.4.5  Coupled Mtb PanD and PanC reaction 
The assays were done with the same enzymatic kit as in previous section.  The assay 
mixtures contained 10mM Hepes, pH 7.8, 10mM MgCl2, 10mM ATP, 5mM D-pantoic acid, 
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PPi reagent, 150µg PanC or 137µg PanC per reaction, 5µg Mtb PanD and ddH2O.  The 
assay mixture was incubated at 30˚C for 5 minutes before initiation of the reaction with 
the addition of L-aspartate.  The concentration of L-aspartate used was 0, 0.025, 0.05, 0.10, 
0.15, 0.25, 0.50 and 1.00mM. 
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C h a p t e r  5  
Conclusion and future directions: 
5.1  Solubility of AofH 
Overexpression of Mtb proteins from the E. coli expression systems are known to often 
give low yields and solubility problems (1).  One of the factors that contribute to this 
problem is the difference in G-C content between the DNA of the organisms.  The G-C 
content of E. coli DNA are about 50% while it is 65-70% of the Mtb proteins (1).  To 
overcome the insolubility problems we investigated the expression of native AofH fused 
to different fusion tags (His, GST, His-GST, Nus and MBP).  Solubility was obtained with 
all the tags except with the His-tag.  AofH fusions with the Lumio™-tag were also created 
for use in fluorescent-based screening in further application.  Methods that increase the 
solubility of the expressed protein and translation efficiency were also employed.   These 
include the co-expression of the AofH fusions with the His-Lumio™- and His-GST-tags 
with the scarce codon tRNAs and the chaperone proteins as contained in the Takara 
chaperone plasmid sets.  Only the co-expression of His-Lumio™ -AofH with the 
chaperone protein trigger factor (Tig) gave soluble expression. 
From this we can conclude that soluble expression of AofH from the E. coli system is 
successful when the enzyme is fused to the various fusion tags.  Other ways to overcome 
the solubility problem may be expression of AofH in a eukaryotic expression system.  The 
use of such expression systems has not been well documented in literature (1).  We have 
identified two yeast systems that may be suitable for the task.  The first system is 
expression in S. cerevisiae, which has already been mentioned in Chapter 2, section 2.4.1.  
Our initial experiments with this system were unsuccessful, but this can be ascribed to the 
use of the wrong detection methods.  The second system that can be used is the Pichia 
pastoris expression system. 
5.2  AofH activity 
Different analytical methods were used to determine the products of the AofH enzymatic 
reactions with the various polyamine substrates.  The first set of analyses was performed 
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by TLC; from these we deduced that AofH forms 3-aminopropanol as a product from all 
the polyamines.  This was an unexpected result, since no other flavin-containing enzyme 
is known to catalyze a similar reaction. Unfortunately we could not confirm this result; in 
fact, AofH seemed to be inactive in every additional analysis performed.  We finally set 
out to confirm the presence of the FAD cofactor in the enzyme by variety of methods. 
These lead us to conclude that the AofH fusions did not contain FAD, and that the 
observed spots on the TLC analysis of the AofH-catalyzed reactions could not be due to 3-
aminopropanol, or that is was formed by some non-enzymatic process.  Further efforts to 
refold the protein in the presence of FAD also failed, as detailed in Chapter 2.  Taken 
together, our study shows that the confirmation of the presumed activity of AofH will 
remain elusive until the enzyme can be purified in its active form, i.e. with bound FAD.  
The expression of AofH from another expression system may help to achieve this goal. 
The functional complementation studies, to determine the enzyme’s activity by genetic 
methods, also proved inconclusive.  We found that whether transformed with pBAD-
EXP49-gus (the negative control) or pBAD-EXP49-aofH ∆panD mutants showed similar 
rates of growth (in solution) in minimal media.  This is an unexpected result, since 
previous reports indicated that PanD is the sole source of β-alanine in E. coli.  This result 
indicates that the ∆panD mutants were able to source β-alanine from other metabolic 
pathways, complicating the determination of whether cell lines containing AofH could 
indeed produce a β-alanine precursor at low levels.  Future studies in this area will have 
to make use of a β-alanine auxotroph that is not E. coli based, preferable a β-alanine 
auxotroph strain of S. cerevisiae (BY4742) or of Mtb itself.   
5.3  Synthesis of PanD inhibitors 
The synthesis of the inhibitor β-fluoroaspartate was more complicated than originally 
anticipated.  Most of the problems experienced were purification-based, while the yield of 
the different synthetic steps was also low.  Although this synthesis is still viable, it may be 
simpler to source the β-hydroxyaspartate precursor commercially and continue the 
synthesis from this step forward.  However, such a step may be prohibitively expensive. 
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5.4  Assay methods 
We successfully developed qualitative and quantitative assays to identify 
inhibitors/substrates of PanD.  Qualitative analyses of PanD enzymatic reactions can be 
performed by reverse phase HPLC to identify whether certain compounds are substrates 
of the enzyme.   
As far as the quantitative method is concerned, we assayed for PanD by coupling the 
formation the β-alanine product to the reaction catalyzed by PanC, and subsequently to 
the the formation of pyrophosphate (PPi).  This assay works well and at a sufficient rate 
for our analysis.  The steady-state kinetics of PanD was determined with this method and 
compares well to literature values.  The effects of inhibitors on the PanD reaction with  
L-aspartate still have to be studied. 
5.5  Conclusion 
The work done by Sasetti et al. (2) indicated that PanD, the enzyme involved in the 
decarboxylation of L-aspartate to β-alanine, is not essential in Mtb.  This implies that an 
alternative source of β-alanine must exist for the survival of the mycobacterium.  After 
careful evaluation of all the possible routes for β-alanine production we postulated that 
the most likely alternative is the oxidation of the polyamines by a polyamine oxidase.  
Mtb AofH was identified as a likely PAO candidate based on sequence homology to the 
FAD-dependent Saccharomyces cerevisiae polyamine oxidase Fms1.  Due to various 
obstacles in the soluble expression and purification of AofH in its active form we were not 
able determine the activity of AofH or whether it has a role in pantothenate biosynthesis. 
Furthermore the results obtained from the functional complementation studies lead us to 
question the validity of the essentiality studies done by Sassetti et al. (2)  In their study the 
essentiality of genes were determined by transposon site hybridization (TraSH).  
Although TraSH gives good indications of the essentiality of genes, the results obtained 
still needs to be verified independently which in this case would be by the creation of a 
∆panD mutant.  Although Sambandamurthy et al. made the double deletion mutant 
∆panCpanD, the essentiality of PanD has not been verified (3). 
We continued our studies of β-alanine biosynthesis by attempting the design a 
mechanism-based inhibitor, β-fluoroaspartate, for the PanD enzyme.  The synthesis of this 
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compound was more cumbersome than anticipated and has to be revisited.  Both 
qualitative and quantitative analytical techniques were designed to compare the reactions 
of PanD with substrate analogues of L-aspartate to each other.  Our results show that β-
substituted aspartate analogues may be good potential inhibitors of Mtb’s PanD protein. 
5.6  References 
(1) Bellinzoni, M., Riccardi, B. (2003) Techniques and Applications: The heterologous 
expression of Mycobacterium tuberculosis genes is an uphill road. TRENDS in 
Microbiology  11, 351-358. 
(2) Sassetti, C. M., Boyd, D. H., and Rubin, E. J. (2003) Genes required for mycobacterial 
growth defined by high density mutagenesis. Molecular Microbiology 48, 77-84. 
(3) Sambandamurthy Vasan, K., Wang, X., Chen, B., Russell Robert, G., Derrick, S., 
Collins Frank, M., Morris Sheldon, L., and Jacobs William, R., Jr. (2002) A 
pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects 
mice against tuberculosis.  Nature Medicine 8, 1171-4. 
 
 
